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1. Short Summary 
Comparative dissolution testing is extensively used as a tool to evaluate equivalency 
between oral solid dosage forms. However the current official procedure to compare 
dissolution profiles, the f2 similarity factor, lacks solid statistical foundation and the 
statistical uncertainty is unknown. Additionally the limits to declare in vitro similarity with 
the current methodology (f2 ≥ 50) are arbitrary and not bound to any biopharmaceutical 
property; therefore it cannot be considered as a good predictor of the in vivo 
performance of formulations, especially in the case of extended release formulations. 
The aim of this work was to design, develop and explore two new statistical tests for 
comparing dissolution profiles. These tests have more statistical foundations than the 
current methodologies and exhibit the flexibility to be customized for a specific 
formulation. One test, the tolerated difference test (TDT) can be tailored to detect 
differences in the release profiles of extended release formulations that represent a lack 
of bioequivalence (or a significant difference in the performance in a combined 
dissolution permeability system). 
Customization of the dissolution profile comparison tests for ER formulations was 
possible by using the TDT without sacrificing its statistical properties (known and 
acceptable statistical uncertainty). 
In summary, a new approach to design and perform dissolution profile comparisons 
under typical principles of statistical experimental design is described. Four 
demonstrative examples of comparisons of ER formulations are presented. 
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2. Kurzzusammenfassung  
Vergleichende Untersuchungen des Auflösungsverhaltens werden häufig zur 
Bestimmung der Äquivalenz von oralen, festen Arzneiformen eingesetzt. Die derzeitige 
offizielle Prüfung, der f2-Test, verwendet hierfür den sogenannten similarity factor f2, 
dem jedoch eine solide statistische Grundlage fehlt und dessen statistische 
Unsicherheit nicht bekannt ist. Darüber hinaus sind bei diesem Test die Grenzen für die 
in-vitro-Ähnlichkeit (f2 < 50) willkürlich gewählt und nicht an biopharmazeutische 
Eigenschaften gebunden. Daher kann diese Methode nicht als eine gute Vorhersage für 
das in-vivo-Verhalten der untersuchten Arzneiformen angesehen werden. Dies gilt 
insbesondere für Arzneiformen mit verlängerter Wirkstofffreigabe. 
Das Ziel dieser Arbeit war die Entwicklung zweier neuer statistischer Tests zum 
Vergleich von Auflösungsprofilen. Im Vergleich zu momentan angewendeten Methoden 
besitzen diese beiden neuen Tests eine fundierte statistische Basis und verfügen über 
die Flexibilität, für spezifische Formulierungen angepasst werden zu können. Einer 
dieser Tests, der Tolerated Difference Test (TDT), kann so angepasst werden, dass 
solche Unterschiede zwischen den Dissolutionsprofilen von verlängert freisetzenden 
Formulierungen identifiziert werden, die auf mangelnde Bioäquivalenz hinweisen. 
Im Rahmen der vorliegenden Arbeit wird ein neuer Ansatz zur Entwicklung und 
Durchführung von Vergleichstests für Dissolutionsprofile beschrieben, die auf Prinzipien 
des statistischen experimentellen Designs basieren. Die Anwendungsmöglichkeiten 
werden anhand von vier Beispielen für verlängert freisetzende Formulierungen 
dargestellt. 
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3. Introduction 
After a drug formulation proves to be safe and effective in human trials, it is crucial to 
demonstrate that later formulations, following changes during drug development, post-
approval stages, or production by generic manufacturers, possess the same efficacy 
and safety profile of the original formulation [1-3]. Because human experiments to prove 
efficacy and safety are highly costly, time consuming and in some cases ethically 
questionable, the pharmaceutical industry is constantly searching for effective 
surrogates for judging therapeutic equivalence of pharmaceutically equivalent drug 
products. One widely accepted and official procedure to ensure efficacy and safety of 
new formulations is the assessment of Bioequivalence (BE), in which an absence of 
significant differences in the rate and extent to which the active ingredient become 
available at the site of drug action must be demonstrated [4-9]. However, under certain 
conditions in vitro testing has been accepted as a sufficiently reliable surrogate for an in 
vivo BE study [10, 11]. When in vitro testing is accepted as a surrogate, the therapeutic 
equivalence of drug formulations is assured by comparison of their dissolution profiles.  
In this chapter, the theory of in vitro equivalence testing and in vivo BE is reviewed, as 
well as the conditions and procedures by which in vitro testing is considered as a 
reliable surrogate for an in vivo BE. 
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3.1. Bioequivalence and Biowaiving 
Testing the bioequivalence between a product, called the Test formulation, and a 
suitable comparator, the Reference formulation, in a pharmacokinetic (PK) study with a 
limited number of subjects is one way of demonstrating equivalence without having to 
perform a clinical trial involving many patients [8]. 
Two products are considered bioequivalent when the rate and extent of absorption of 
the Test formulation do not show a significant difference from the rate and extent of 
absorption of the Reference formulation when administered at the same molar dose of 
the active pharmaceutical ingredient (API) under similar experimental conditions [12]. 
As a prerequisite both formulations must have the same pharmaceutical form and the 
same qualitative and quantitative composition in active substances. 
In bioequivalence studies, plasma concentrations obtained after administration of the 
Test formulation are contrasted to those of a Reference formulation. Pharmacokinetics 
(PK) parameters as maximum plasma concentration (Cmax) and Area Under the Curve 
(AUC) from both formulation are compared through 90% confidence intervals (90% CI ) 
around the ratio of the estimated geometric means between the contrasted formulation. 
Acceptance criteria used by most regulators are that the 90% CI of the Test/Reference 
geometric mean ratios for AUC and Cmax should fall within 80-125% limits [4, 6-8, 12]. 
Most regulatory entities recommend that a BE study enroll at least 12 healthy volunteers 
to ensure reliable estimates but some jurisdictions suggest 18 or 24. Differences among 
guidelines to establish BE vary from one jurisdiction to another not only in the 
recommended number of subjects but also in: 1) use of volunteers or patients, 2) 
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administration of food, 3) PK parameters to be compared, 4) measurement of parent 
drug or metabolite, and 5) strength to be investigated [12, 13]. 
 When the excipients of a formulation do not affect the absorption of the API, the API is 
not a prodrug, does not have a narrow therapeutic index and is not intended to be 
absorbed in the oral cavity, in vitro testing has been accepted as a sufficiently reliable 
surrogate for an in vivo BE study [10, 11]. The regulatory acceptance of in vitro testing 
as a reliable surrogate for an in vivo BE is referred as “biowaiver” [10, 11]. 
Requirements for granting a biowaiver of an in vivo BE study depend on the class of 
drug, type of formulation, the type of post-approval change and the information 
available. Drugs are normally classified according to their solubility and intestinal 
permeability. In 1995, Amidon et. al. [14] introduced the biopharmaceutical classification 
system (BCS) which classifies drugs as follows. 
 Class I :  high solubility – high permeability 
 Class II :  low solubility – high permeability 
 Class III :  high solubility – low permeability 
 Class IV:  low solubility – low permeability 
For immediate release (IR) solid oral dosage forms of BCS class I drugs demonstration 
of ≥ 85% dissolution in one or several media in 15 min is normally enough for conceding 
a biowaiving of BE studies in the case of post-approval changes of minimal impact [11]. 
Debate is still open as to whether biowaiving could be accepted for IR formulations of 
other BCS class drugs and guidelines differ in this point [10, 13]. Likewise, biowaiving of 
ER is not granted in all jurisdictions and in those where it is accepted a IVIVC model 
must be employed to justify the decision.  
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3.2. Drug Dissolution Tests 
In vitro dissolution studies are commonly used in drug manufacturing to monitor process 
control, minor formulation changes and manufacturing site changes [15]. Originally, the 
dissolution test was used primarily as a formulation development tool and as a quality 
control test for determining that the API would dissolve in vivo [16]. Currently, 
dissolution is the only test that indicates if a dosage form will dissolve in the patient and 
is accepted as an indicator of the ability of the dosage form to release the API and 
enable it to become available at its site of action [17]. For that reason dissolution tests, 
at first exclusively used as quality control test, have been emerging as a surrogate 
equivalence tests for certain categories of orally administered pharmaceutical products 
[8]. 
The most commonly employed dissolution test methods are the basket method (USP 
Apparatus 1) and the paddle method (USP Apparatus 2) [18]. These methods are 
simple, robust, well standardized regarding volumes and agitation, and used worldwide 
[19]. Recently a flow-through cell system (USP apparatus 4) that aims to mimic sink 
conditions has also received much attention because of its flexibility for research and 
development. This dissolution technique has been proven to be reproducible and 
robust, which is an important characteristic for dissolution testing [20].  
Dissolution testing should be carried out under physiological conditions which normally 
includes temperature of 37 ± 0.5°C and aqueous medium with pH range 1.2 to 6.8. The 
inclusion of biorelevant media is also possible and advances in developing more 
biorelevant dissolution methodologies have been continuously made [21-27], and have 
been identified as a major priority [28, 29].  
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3.3. Modeling Drug Dissolution  
The quantitative analysis of the data obtained from dissolution tests is deeper when 
mathematical formulas that express the dissolution results as a function of some 
characteristics of the dosage forms are used. In some cases, these mathematic models 
are derived from the theoretical analysis of the release process. In most of the cases a 
mechanistic expression is not available and some empirical equations have proven to 
be suitable [30]. Drug dissolution from solid dosage forms has been described by kinetic 
models in which the accumulated mass dissolved is a function of time.  
Dissolution data is most commonly (but not always) described by the following 
mathematical dissolution models: 
- Zero order kinetics [31]: 
  
  
      equation 1 
Where    is the accumulated mass is dissolved at time t and   is the mass dissolved 
at infinite time, and k0 is the zero order release constant. According to this model the 
drug is released is at a constant rate.  
- Firs order kinetics [32]: 
  
  
       
equation 2 
In which the rate of drug release is proportional to the remaining (not released) quantity 
of drug in the formulation. And k is the proportional constant. 
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- Higuchi Model [33] : 
  
  
    
 
  
equation 3 
Where b is the Higuchi dissolution constant. This expression attempts to describe a 
nonlinear release kinetics with higher release rates at the beginning of the dissolution 
test. 
- Korsmeyer model [34]: 
  
  
      
equation 4 
This model is a semi-empirical expression in which k is a constant incorporating 
structural and geometric characteristics of the drug dosage form, n is the release 
exponent, indicative of the drug release mechanism, and the release rate is proportional 
to the remaining drug in the formulation. Values of       indicate Fickian release, 
values of           indicate an anomalous (non-Fickian or coupled 
diffusion/relaxation) drug release, and values of       indicate a case II (relaxation-
erosion controlled) drug release. 
- Peppas model (equation 5) [35] 
  
  
     
      
   
equation 5 
In which    is the diffusional constant,    is the relaxation constant and   is the 
diffusional exponent, the latter depends on the geometrical shape of the releasing 
device through its aspect. 
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- Weibull model [36, 37] [38]: 
  
  
   (      (   )
 
) 
equation 6 
Where ,    and β is a shape parameter that can also indicate the release mechanism 
[38]. 
- Hill model [39]: 
  
  
   
   
   
    
 
equation 7 
In which t50 is the time at which 50% of the drug is released from the formulation and   
is a shape parameter. Another mechanistic expressions such as Noyes-Whitney, 
Nernst-Brunner, and Hixson-Crowell has been widely used to describe drug dissolution 
of solids but have very limited applicability in describing release from complete dosage 
forms [40].  
 
3.4. Dissolution Profile Comparisons 
When the biowaiving of drug formulations is possible, the therapeutic equivalence of 
drug formulations is assured by in vitro comparison of dissolution profiles. The term 
similarity has been employed to describe the lack of difference between dissolution 
profiles from two different sources (formulations) and it is normally established by using 
a similarity factor [2, 19, 41, 42] presented in 1996 by Moore and Flanner [41] (equation 
8) to compare dissolution curves. They introduced this method as especially 
recommended for use in stability studies and optimization during product development 
and scale-up. Since f2 has been proposed, several publications have explored the 
advantages and disadvantages of f2 [30, 43, 44] and some modifications, such as the 
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constructions of confidence intervals have been proposed [45, 46]. Presently, f2 is 
employed and recommended by regulatory authorities for scale-up and post-approval 
changes; however, the level of confidence of the method is uncertain and several 
publications have shown it to have low statistical power [30, 43].  
             {[  
 
 
 ∑   (      )
 
 
   
]
    
       }   equation 8 
In equation 8, Rt is the mean of the dissolved drug from the Reference batch at time t, Tt 
is the mean of the drug dissolved from the Test batch at time t, n in the number of time 
points and wt is a weight factor that can be used to enhance the influence of particular 
time points. If the calculation yields f2 ≥ 50, similarity of R and T is declared.  
FDA guidelines [19] recommend testing 12 tablets of each batch. Theoretically, if the 
difference in drug dissolution between R and T is exactly 10% at every time point, the 
value of f2 is 50; if the differences are >10% (at every time point), f2 becomes smaller 
than 50, and if the differences are smaller (<10%) f2 becomes larger than 50. However, 
values of f2 above 50 can be obtained with differences greater than 10% at some 
particular time points if the differences at the other points are small enough to 
compensate for the larger differences; thus, the basis for choosing a value of 50 as the 
rejection criterion is questionable. To alleviate this problem, Moore and Flanner included 
the weight factor wt in the expression; however, there is no clarity on how to employ the 
weight factor and it can highly favor (intentionally or unintentionally) either similarity or 
non-similarity. The FDA guidelines [19] also mention the weight factor but allow the 
researcher to decide whether to use it or not. Another disadvantage of using f2 is that 
the arithmetic mean is very susceptible to extreme values and this may result in large 
differences between individual tablets being ignored. 
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Apart from f2, several methodologies for comparing dissolution profiles have been 
described [30, 47]: 
Adaptations of single value comparisons of level B parameters (area under curve, mean 
dissolution time, time to reach 85% of dissolution etc.) have not been well accepted 
because it is often not possible to properly include the information for every time point in 
such comparisons. 
Multivariate analysis [48, 49], requires assumptions that are difficult to fulfill. Moreover, it 
is questionable whether comparison of dissolution profiles should be consider as 
multivariate problem, because the same variable is measured repeatedly over time.  
Model-dependent methods have also been used, but these rely highly on fitting to a 
specific dissolution model, and in some cases such a model is not available. Moreover, 
model-dependent methods are still bound to multivariate distances with the 
aforementioned problems [50]. Factors as f2 which are easy to be implemented have 
been widely employed, but normally lack scientific justification [30] or statistical support.  
 
3.5. In vitro-in Vivo Correlation Models 
ER formulation are dosage forms usually designed to achieve safer and more constant 
in vivo concentrations of the administered drug or to decrease the administration 
frequency to improve compliance in the patient [29].  
Currently, biowaiver of ER drug formulations can only be granted when an IVIVC model 
is available. These IVIVC models are defined as a predictive mathematical model 
describing the relationship between an in vitro property of a dosage form and a relevant 
in vivo response [2]. The term correlation in IVIVC is due to the fact that in some cases 
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the strength of the relationship between parameters derived from the in vitro and in vivo 
studies are quantified by the Pearson correlation [15].  
An acceptable IVIVC requires that the in vitro dissolution and in vivo release or 
dissolution behavior of a dosage form should be either similar or have a scalable 
relationship to each other. IVIVC could only be established when the factor controlling 
the appearance of the drug in the blood flow is linked with the formulation (slow release) 
and not with any physiological limiting factor (for example permeability) [51].  
IVIVC have been divided into three groups: 
Level A: The entire in vivo time course (normally plasma concentrations) is predicted 
from the in vitro data.  
Level B: Correlation between a statistical moment of the in vitro dissolution (mean 
dissolution time MDT) and a statistical moment of the in vivo plasma levels (mean 
residence time). 
Level C: Single point relationship between a dissolution parameter and a PK parameter.  
Traditionally IVIVC models have been performed through the use of convolution and 
deconvolution processes to find mathematical functions able to connect the in vitro and 
in vivo mathematical functions. However, these methodologies are not based on 
biopharmaceutical principles or mechanistic expressions that allow a more detailed 
description of the in vivo situation. Recently some mechanistic IVIVC models have been 
introduced to overcome this weakness [52, 53].   
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3.6. Permeability and d/p-systems 
Apart from the release kinetics the bioavailability of an orally administered drug is also 
determined by the intestinal permeability. However, these two properties are normally 
evaluated separately in vitro which restricts the possibility of studying the effects of drug 
formulations on absorption. Therefore, a tool to simultaneously study in vitro dissolution 
and permeability can be of great utility during the drug formulation development process 
to study the effect of drug release and excipients on oral absorption in an easy and 
inexpensive way, which ultimately can lead to an optimization of the drug formulation. 
Several approaches have been described to study dissolution and absorption 
simultaneously in the same experimental apparatus [54-59], however, the only set-up 
that allows the evaluation of complete solid oral dosage forms in an open system using 
dynamic flow conditions is the one developed by Motz et al [60]. Moreover, this 
combined dissolution and permeation system (d/p system) has been improved to allow 
continuous measurements of the drug concentrations in the different compartments of 
the device [61] and continuous monitoring of the Caco-2 cells monolayer integrity by 
measuring the transepithelial electrical resistance (TEER) [62]. The d/p-system has also 
been recently adjusted to perform experiments with artificial membranes [63]. 
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3.7. Aim of this Work 
The current official procedure to compare dissolution profiles, the f2 similarity factor, 
lacks solid statistical foundation. The level of statistical uncertainty when this 
methodology is employed is therefore unknown. Additionally, the limits to declare in vitro 
similarity with the current methodology (f2     ) are arbitrary, and as they are not 
bound to any biopharmaceutical property, they cannot be considered as a good 
predictor of the in vivo performance of formulations, especially when ER formulations 
are considered. On the other hand, two major characteristics are needed in statistical 
tests for performing dissolution profile comparison: high statistical power and flexibility 
to perform in a variety of scenarios. Because these two properties are not likely to be 
fulfilled by the same test, two separate tests, each with one of the aforementioned 
properties, were designed in this thesis as a new methodology to compare dissolution 
profiles. The intention in this respect was to design, develop and explore new 
dissolution profile comparison tests (DPC-tests) with more statistical basis that the 
current methodologies (f2 similarity factor), and to link the limits of rejection of these 
DPC-tests with significant differences in relevant biopharmaceutical properties, so as to 
achieve a greater predictive power of the in vivo performance of formulations. In more 
detail, the major aims of this thesis were: 
 To design, present and explore the statistical robustness and statistical power of 
two new tests based on nonparametric permutation test theory. The first test, 
called permutation test (PT), was designed to detect small differences in 
dissolution profiles and very stringent to confer similarity. The second test, called 
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tolerated difference test (TDT), designed with the required flexibility to be 
customized according to the requirements of any particular case. 
 To develop drug-specific DPC-test for three ER formulations (metformin, 
diltiazem and pramipexole) using IVIVC models, computer simulated BE trials 
and permutation tests. It was intended that these customized tests should be 
able to detect, at a known level of certainty, differences in release profiles 
between ER formulations that represent a lack of BE.  
 To investigate the effect of DPC-test conditions, BE-trial conditions, and 
drug/formulation properties in the determination of biorelevant limits of the DPC-
test. 
 To apply the concept of DPC-test customization in a combined dissolution 
permeability system (d/p-system) in order to identify as in vitro similar, only 
formulations that would not differ significantly in the permeated amount achieved 
in the permeability module of that system. 
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4. Two New, Nonparametric Test for Statistical Comparison of 
Dissolution Profiles 
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4.1. Abstract 
The most popular way of comparing oral solid forms of drug formulations from different 
batches or manufacturers is through dissolution profile comparison. Usually, a similarity 
factor known as (f2) is employed; However, the level of confidence associated with this 
method is uncertain and its statistical power is low. In addition, f2 lacks the flexibility 
needed to perform in special scenarios. In this study two new statistical DPC-tests 
based on nonparametrical permutation test theory are described, the permutation test 
(PT), which is very restrictive to confer similarity, and the tolerated difference test (TDT), 
which has flexible restrictedness to confer similarity, are described and compared to f2. 
The statistical power and robustness of the tests were analyzed by simulation using the 
Higuchi, Korsmeyer, Peppas and Weibull dissolution models. Several batches of oral 
solid forms were simulated while varying the velocity of dissolution ( from 30 mins to 
300 mins to dissolve 85% of the total content) and the variability within each batch (CV 
2% to 30%). For levels of variability below 10% the new tests exhibited better statistical 
power than f2 and equal or better robustness than f2. TDT can also be modified to 
distinguish different levels of similarity and can be employed to obtain customized 
comparisons for specific drugs. In conclusion, two new methods, more versatile and 
with a stronger statistical basis than f2, are described and proposed as viable 
alternatives to that method. Additionally, an optimized time sampling strategy and an 
experimental design-driven strategy for performing dissolution profile comparisons are 
described.  
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4.2. Introduction 
Comparing time profiles for dissolution data or for any other type of data is a complex 
statistical challenge. The highly correlated nature of this type of data, which exists in 
spite of its mostly unknown mechanisms, the many types of curves observed in 
dissolution profiles, the high variability combined with the finite nature of the variable 
(≤100%), and the fact that two curves may cross producing both positive and negative 
differences, make it difficult to determine whether two curves should be regarded as 
similar or different, and therefore represent a major barrier to an adequate solution to 
this problem [30, 41, 64]. When a variable is measured over time and compared under 
two or more conditions, a simple and commonly used technique is to compare the value 
of the variable at one or two particular time points and to test hypotheses about 
differences in the variable between the different conditions at these precise time points 
[65]. Although this approach is adequate in a broad variety of situations, it fails, when 
the major interest lies in the kinetic of the process, as when drug dissolution profiles are 
compared.  
 Drug dissolution assays of oral solid dosage forms are designed to predict the 
performance of these formulations in the gastro-intestinal tract (GIT) and ultimately 
provide information about the bioavailability of oral formulations. The information 
obtained at each time point can be crucial because the absorption of drugs varies 
across the GIT due to the different membrane properties of the mucosal cells, the local 
microclimate and, the presence or absence of transporters, enzymes and other 
substances ([66], [67], [68] and [69]). Because of this, comparisons using data obtained 
at only one or two time points are insufficient. Comparisons of areas under the curve 
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are also inadequate because two curves can have very similar areas under the curve 
but present important differences at single time points, especially if the two profiles 
cross [41]. To date, there is no satisfactory statistical tool, either for dissolution profiles 
or for other types of data that completely solves this particular problem.  
In 1996, Moore and Flanner [41] described the use of an expression that they called f2 
(equation 8) to compare dissolution curves. Since f2 has been proposed, several 
publications have explored the advantages and disadvantages of f2 [30, 43, 44] and 
some modifications, such as the constructions of confidence intervals have been 
proposed [45, 46]. Presently , f2 is employed and recommended by regulatory 
authorities for scale-up and post-approval changes; in addition it can be used to waive 
clinical bioequivalence studies (at least under certain conditions) for immediate release 
and modified release solid formulations [19],[2, 4]. However, the level of confidence of 
the method is uncertain and several publications have shown it to have low statistical 
power [30], [43].     
Apart from f2, several methodologies for comparing dissolution profiles have been 
described [30] [47] like adaptations of single value comparisons of level B parameters, 
(area under curve, mean dissolution time, time to reach 85% of dissolution etc.), or 
multivariate analysis [48, 49], and model-dependent methods. However these 
methodologies have not been accepted by the industry because of its statistical and 
conceptual limitations (section 3.4). Factors as f2 which are easy to implement has 
been widely employed, but normally lack scientific justification [30] or statistical support.  
Most available statistical tests are designed to detect differences, rather than to prove 
similarities, and a lack of difference does not necessarily imply similarity. However, 
Two New, Nonparametric Test for Statistical Comparison of Dissolution Profiles 
______________________________________________________________________________ 
20 
demonstration of a lack of difference with quantified and adequate type-I and type-II 
errors would provide a more solid statistically method for detecting similarities than a 
method based on subjective limits.  
The power of a statistical test is the probability that the test will reject the null hypothesis 
(in this case similarity) when the null hypothesis is false (i.e. the probability of not 
committing a type-II error, or making a false negative decision). With the help of 
dissolution models (equations 1-7), scenarios when the null hypothesis is false can be 
generated (differences in the value of one or more parameters), and the power of the 
tests can be evaluated. The more powerful a test is, the smaller difference it can detect 
in the value of model parameters.  
A more powerful DPC-test (able to detect small differences between two profiles) would 
be very valuable for comparing the dissolution profiles of formulations containing drugs 
with very narrow therapeutic windows and/or drugs classed as II, III and IV in the 
Biopharmaceutical Classification for which in vivo bioequivalence can require a more 
strict, almost identical in vitro similarity [14]. It can also be postulated that for a 
transporter substrate (active transport or efflux) of a transporter present in enterocytes, 
the effective concentration in the intestinal lumen may play a decisive role in 
determining the bioavailability of the compound. Very powerful statistical tests are 
needed, indeed, to detect small differences in dissolution profiles to assure similarity of 
two products from different manufacturers or from the same manufacturer after a major 
or minor change in production technology. In a large number of cases, the bioavailability 
of two different drug products with the same active molecule will be very similar if their 
dissolution profiles, evaluated under the relevant conditions [21], are very similar.  
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On the other hand, for some compounds, large differences in dissolution profiles are 
necessary to produce significant differences in bioavailability, and a test less strict than 
f2 is also needed[70] [44]. In general, a flexible DPC-test that offers variable power 
according to specific needs, but still retains adequate levels of robustness and statistical 
uncertainty, is highly desirable. 
Aware of the expectations that dissolution and drug release will play an even wider role 
in regulating quality generic drug products in the future [71], two major characteristic are 
needed in statistical tests for dissolution profile comparison: High statistical power and 
flexibility, as these two properties are not likely to be fulfilled by the same test, two 
separate tests, each with one of the mentioned properties may be an adequate solution. 
In this study two new statistical DPC-tests based on nonparametric permutation test 
theory are presented, and their ability to satisfy the above mentioned requirements 
(more restrictiveness and more flexibility) is assessed. The first, called permutation test 
(PT), is capable of detecting small differences in dissolution profiles and is very exigent 
to confer similarity. The second one, called tolerated difference test (TDT), the level of 
exigency to confer similarity can be modified to detect large or small differences 
according to the requirements of any particular case. Both tests were explored in terms 
of statistical robustness and power and were compared to f2 and bootstrap 95% 
Confidence Intervals of f2 (C.I.) [45, 46].  
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4.3. Methods 
4.3.1.  Dissolution Models 
Dissolution data were simulated following five different mathematical dissolution 
models. i.e., the Higuchi model (equation 3) [33], the Korsmeyer model (equation 4) 
[34], the Peppas model (equation 5) [35] , the Weibull model (equation 6) [36, 37] [38] 
and the Hill model equation 7 [39]. 
 
4.3.2. Data Simulation 
4.3.2.1. Reference and Test Formulations 
Reference formulations were modeled as follows: 
Higuchi Model:                            
Korsmeyer Model:           ;                    
Peppas Model:          
   ;          
         ;           
Weibull Model:          
  ;       ;              
Hilll Model:             ;       ;              
 
4.3.2.2. Intrinsic and Residual Variability 
Test formulations were modeled by varying the models parameters around those of the 
Reference formulations to obtain a wide range of dissolution profiles (85% of labeled 
drug dissolved in 30 to 300 min). For each individual tablet, intrinsic (parameters of the 
model) and residual variability (experimental error), variability was included. Intrinsic 
variability was included for all parameters. 
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equation 9 
Where    is the parameter for the i-th tablet,    is the parameter of the batch and ƞ is the 
intra-batch variability with mean value zero and variance    (   (    )) 
The residual variability (experimental) was described by: 
           
  
equation 10 
Where     is the simulated dissolved amount (%) of drug from the i-th tablet at the j-th 
sample time,        is the predicted dissolved amount (%) of drug from tablet i at the j-th 
sample time and   is the residual (experimental) variability with mean value zero and 
variance    (   (    )). In summary, for each single tablet one or more individual 
parameter are calculated according to equation 9, the number of parameters depends 
on the model and, ranges from one parameter in the Higuchi model to three parameters 
in the Peppas Model. Finally, a predicted value is calculated for each time point 
according to the models employed (equations 3-7, section 3.3) and the residual 
variability is also incorporated according to equation 10. 
According to equation 9equation 10), the variability within the batches is due to the 
values of  and  employed in each simulation. For every model (equation 3equation 
7) several combinations of  and  at different T85 were studied to address the effects 
of these values on variability. For each combination of T85,  and 10.000 batches 
were simulated and the CV at each time point for every batch was analyzed. The 95% 
percentile of all the measured CV’s was recorded as CV95 as a measure of global 
variability. 
As can be observed in Figure 4.1, no significant differences in CV95 were found for 
batches with different T85 for data following the Higuchi model at different T85, the same 
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effect was observed for all the models; however, visualization is not as simple because 
more than one  is present in each case. 
 
Figure 4.1. Intrinsic and residual variability of the simulated batches (Higuchi Model). 
Setting up of intrinsic and residual variability in the simulated tablets batches according to equation 9-
10) Contour Plot of cv for different combinations of    and   . The result were almost identical for 
batches of tablets with different t85 under Higuchi model. 
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4.3.2.3. Sampling Time Points  
 
For every condition, a set of values for 12 tablets was generated. Time points were 
established according to the following scheme: 
t85 ≤ 40 minutes      sampling every 5 minutes 
40 < t85 < 60 minutes      sampling every 10 minutes 
60 ≤ t85 < 90 minutes      sampling every 15 minutes  
90 ≤ t85 < 150 minutes      sampling every 20 minutes  
t85 ≥ 150 minutes       sampling every 30 minutes 
where t85 = time at which 85% of labeled drug is dissolved. According to the current 
guidelines [19] only one time point with average dissolved drug higher to 85% is 
considered.  
 
4.3.3. Dissolution Profile Comparison Tests 
In a typical dissolution profile comparison (Reference vs. Test) two Matrices (Reference 
and Test) of data points; R (m × n) and T(m × n) are evaluated, being m the number of 
tablets (normally 12) and n the number of time points sampled. The data for every tablet 
are expressed as a vector of length n which length is defined by the number of time 
points sampled in the dissolution profile.  
 
4.3.3.1. f2 Similarity Factor 
f2 similarity factor was calculated according to equation 8. If the calculation yielded f2 ≥ 
50 similarity of R and T was declared. 
 
Two New, Nonparametric Test for Statistical Comparison of Dissolution Profiles 
______________________________________________________________________________ 
26 
4.3.3.2. f2 Bootstrap Confidence Interval (f2 CI)  
Bootstrap 95% Confidence Intervals (CI) of f2 were calculated similar to ones described 
in the literature [45] [46]. Initial simulations were performed to establish the number of 
repetitions to be used. As shown in Figure 4.2, 5000 repetitions produced acceptable 
estimations and allowable computation time. 
 
Figure 4.2. Simulations for determining the number of bootstrap repetitions to employ. The 
variance of the estimator is reduced increasing the number of repetitions. For a very large number of 
repetitions the bootstrapping estimates will converge to one value of CI-lower limit. It was observed 
that after 5000 repetitions, any estimation is not farther than 0.5 units from the converged value at 
large repetitions (200.000). To evaluate the impact of this difference the number of rejections for CI-
lower limit < 50 and for CI-lower limit < 49 were recorded in all the experiments and compared. There 
was no significant change (less than 1%) in robustness or power by this modification. 
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4.3.4. Two New Nonparametric Tests for Statistical Comparison of 
Dissolution Profiles 
 
4.3.4.1. Permutation Test  
Figure 4.3 illustrates the procedure for the permutation test (PT). In this procedure, the 
mathematical distance D0, a square difference between means at every time point is 
used. This value is stored as the Original Distance or D0. Data from every tablet can be 
represented as a vector of length n, a set of 2 × m vectors now representing the data of 
the Reference and Test batches. The first subset of m vectors represents the Reference 
batch and the last subset of m vectors represents the Test batch. After D0 is calculated, 
the vectors are randomly sampled without replacement. In this way, each vector is 
relocated randomly in new Reference or Test subsets, creating two new (m x n) 
matrices Ri and Ti. The same distance D between Ri and Ti is calculated and the value 
is stored as Di. This cycle is repeated 5000 times and an empirical distribution of the Di 
values (5000 values of Di) is built. According to a predetermined type I error (typically, 
alpha = 0.05), a rejection value that is greater than the 1-alpha percent of all Di values 
in this empirical distribution is calculated. If the profiles are similar, D0 is expected to be 
bellow this rejection value; D0 above the rejection value indicates lack of similarity 
between the two profiles. 
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Figure 4.3. Methodology of PT. Illustrative representation of PT methodology, In this case the 
number of tablets m = 12, first D0, is calculated between the two profiles. Then each vector is 
randomly located in new reference or test subsets creating two new (m × n) matrices Ri and Ti . The 
same distance D is calculated between Ri and Ti and the value is stored as Di . This cycle is repeated 
5000 times or more (500,000 in this example) and an empirical Distribution of the Di values (all the 
500,000 values of Di) is built. According to an established type I error (alpha = 0.05), a rejection 
value is indicated in this empirical distribution. A and B show distribution of Di for similar and not 
similar profiles respectively, because it is an empirical distribution the shape is similar but not 
identical, it can be observed than in not similar profiles D0 is bigger than the rejection value and 
therefore similarity hypothesis is rejected. 
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4.3.4.2. Tolerated Difference Test  
This test is based on a tolerated difference ( ) in dissolution between two tablets at 
each time point. Following the concept that there is some difference in percentage of 
dissolved drug that can be tolerated, this test attempts to statistically prove whether the 
differences between the Reference and Test samples exceed the predetermined 
tolerated difference or not. 
Having at any time point the dissolved drug for m tablets from the Reference and m 
from the Test  
Rt1, Rt2, Rt3, . . . , Rtm  ; Rti= dissolved drug of i-th tablet from the Reference at time t  
Tt1, Tt2, Tt3, . . . , Ttm, ;  Tti= dissolved drug of i-th tablet from the Test at time t 
differences between all Rti and Tti are evaluated, and the number of events for which this 
difference is greater than the established tolerated difference ( ) is counted. 
For a single time point, under the null hypothesis               the random variable 
Dd, the number of events in which difference is greater than  , has a discrete distribution 
easy to calculate. For several time points the same procedure is followed but the 
statistic Dd is expressed as: 
   
 
 
∑  
 
   
 
equation 11 
Where Di = the sum of differences greater than  at the i-th time point. In this work, 
values of  = 5 (TDT-1) and  = 10 (TDT-2) were analyzed. The distributions of    for m 
= 12 and n = (1,2,3, . . . ,12) are shown in Figure 4.4. 
For m = 12 or less the exact discrete distribution of  can be calculated without 
difficulty for values of n ≤ 5. For any increment in the value of n the computational time 
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required to calculate the distribution of  is m 2 times longer, and not easily shortened 
by using parallel computing. In this work we calculated for m =12 the exact distribution 
of  for values of n = (1, 2, 3, 4 and 5). Distributions for higher values of n were built by 
simulation with 100.000.000 repetitions. This value was sufficient to produce a 
distribution that differed less than 10e-5% from the exact distribution for the case of n = 
5. (Table of rejection values for TDT is in A.1) 
 
Figure 4.4. Discrete distribution of Dd for different values of n for 12 tablets. n represents the 
number of time points sampled in the comparison, the figure presents the probability of all the 144/n 
values, increasing n produces more leptokurtic shapes and narrower rejection values. For example for 
alpha = 0.05, rejection values are 101 for n = 1, 86.25 for n = 4 and 81.0 for n = 10. Proximity of 
points must not be confused with continuous distribution. 
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4.3.5. Robustness Explorations 
Under conditions of similarity, in which the Reference and the Test formulations have 
equal parameters values in the dissolution models employed. Pairs of Reference-Test 
batches were generated at different levels of variation. Every pair of batches was 
compared using the four procedures described (f2, CI, TDT and PT). At every level of 
variation 5000 pairs of batches were generated and the percentage of rejections (no 
similarity) was evaluated for each method. Ideally, under conditions that satisfy the null 
hypothesis (in this case, similarity), a robust statistical test does not increase the level of 
rejections at increasing levels of variation. In the best case, the level of rejections 
should be constant and very similar to the set type I error of the test (normally 5%) in 
order to quantify uncertainty. Variation in the models were generated including intrinsic 
and residual variability, the 95% percentile of all the measured CV’s at all-time points 
was recorded as CV95 as a measure of global variability. In preliminary experiments, 
stable (no difference with increment in repetitions) values of percentage of rejections 
were found at 2000 repetitions, internal validation with sets of 2000 from the 5000 
repetitions were also made and there was no difference in the results.  
 
4.3.6. Power Explorations 
Under conditions of non-similarity (different parameters values in the model employed) 
pairs of Reference-Test batches were generated at different levels of variation. As in the 
Robustness analysis, each pair of batches was compared using the four procedures 
described (f2, CI, TDT and PT). Differences in parameters were designed to produce 
values of t85 ranging from 60 to 300 minutes. For Korsmeyer, Peppas and Weibull 
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models in which more than one parameter describes the kinetic of the process, 
differences in single parameters (keeping the others constants) and bidirectional 
differences (varying two parameters simultaneously) were explored. At every condition, 
5000 pairs of batches were generated and the percentage of rejections (%detections of 
no similarity) was evaluated for each method. More powerful tests are expected to 
detect smaller differences in the parameters used. As for the robustness experiments, 
stable values of percentage of rejections for both robustness and power were found at 
2000 repetitions in preliminary experiments.  
 
4.3.7. Effect of Statistical Independence and Sample Size 
It must be considered that equation 11 is completely operative only if all    are 
independent and identically distributed (iid) which may be not the case in a typical 
dissolution profile, because only one determination is allowed for each tablet and for 
each time point, this implies that for a typical case of 12 observations at 5 different time 
points, 60 individual tablets must be evaluated under independent conditions (iid-
conditions). Although this may seem fatiguing, it could be well worth the effort in order to 
reduce or completely avoid in vivo studies. Therefore, all explorations were made under 
normal conditions (typical dissolution profile with questionable independence) as well as 
under independent conditions (iid-conditions). The options of using only 6 and 3 
observations per time point (options requiring 30 or 15 tablets, respectively, for 5 time 
points), were also evaluated. To simulate iid-conditions, a new tablet (with the same 
parameters and intrinsic and residual variability) was generated to estimate the 
dissolved drug at each time point; n × m tablets are needed and each tablet was 
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evaluated just one time. Results were obtained under both conditions for all the 
comparison tests to evaluate the influence of independence in the comparisons. 
Additionally, sample size of n = 6 and n = 3 tablets were generated under iid-conditions 
to evaluate the influence of sample size in the comparisons. 
 
4.3.8.   Software 
All the analyses, simulations and statistical tests were performed using the R software 
environment for statistical computing and graphics (version 2.14.2. R Development core 
Team 2013). 
 
4.4.   Results and Discussion 
4.4.1.   Statistical Robustness 
All presented tests showed good robustness for standard (CV95 ≤ 0.1) conditions. Figure 
4.5 shows that the percentage of rejections remains under 0.05 for values of CV95 ≤ 0.12 
and sample size n = 12 tablets for all the tests and models. The robustness of the tests 
was always in the same order (from less robust to more robust) i.e., TDT<CI<f2<PT. 
 
4.4.2.  Effect of Statistical Independence and Sample Size on 
Robustness 
Sample size and iid-conditions did not affect significantly the robustness of the tests, in 
all cases the rejection levels remained within the desired limits (≤0.05) for values of 
CV95 ≤ 0.1 as shown for the Korsmeyer model in Figure 4.6 The summary of the effect 
of statistical independence and sample size for all models is display in Table 4.1 
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Robustness of f2 in not affected by iid-conditions but evidently reduced with smaller 
sample sizes. Robustness of CI is evidently increased under iid-conditions, and 
evidently reduced with smaller sample sizes.  
 
Figure 4.5. Robustness comparison of the presented tests under different dissolution 
models. In each model, pairs of similar batches were generated (batches with the same parameter 
values in equations 2-5) and the percentage of rejections is measured at different levels of variation 
(CV95). Dotted line at 5% indicates the ideal percentage of rejections. All of the tests have acceptable 
levels of Rejections for values of cv ≤ 0.12. f2, and PT show ideal levels of rejection for values of cv ≤ 
0.3 in all the models. 
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Robustness of TDT is slightly increased under iid-conditions and evidently increased 
with smaller sample sizes. Robustness of PT Is not affected by iid-conditions or smaller 
sample size except for n ≤ 3 where the total number of possible permutations does not 
allow useful comparisons. 
 For conditions of high variability (CV95 ≥ 0.2) just f2 and PT showed acceptable levels 
of rejections. PT was the only test in which the level of rejections remained under 5% for 
CV95 ≥ 0.3 in all the models and conditions studied. 
 
Figure 4.6. Effect of iid-conditions and sample size on test robustness (Korsmeyer model).  
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Table 4.1. Effect of iid conditions and batch size in Robustness for all the models and tests 
 
Model & Test 
 
 
Effect of iid conditions 
 
 
Effect of smaller sample 
 Size 
 
Higuchi f2 + - - 
Higuchi CI + + - - 
Higuchi TDT - - 
Higuchi PT ( ) ( )* 
Korsmeyer f2 ( ) - - 
Korsmeyer CI + + - - 
Korsmeyer TDT + + + 
Korsmeyer PT ( ) ( )* 
Peppas f2 + - - 
Peppas CI + + - - 
Peppas TDT + + + + 
Peppas PT ( ) ( )* 
Weibull f2 ( ) - - 
Weibull CI + + - - 
Weibull TDT ( ) + + 
Weibull PT ( ) ( )* 
 
 
 
 
 
4.4.3.  Statistical Power 
Figure 4.7 illustrates how, under the Higuchi model, the level of rejections increases in 
all the tests when the difference between bTest and bReference becomes greater, in other 
words, when the simulated Reference and Test batches are more different. As shown 
here for the Higuchi model with sample size n = 12 and no-iid conditions, PT was the 
+  :  Slight increase in Robustness 
+ + :   Evident increase in Robustness 
-  : Slight decrease in Robustness 
- - : Evident decrease in Robustness 
( ) : No apparent effect 
( ) * For batch size = 3, level of rejections of PT remain at 0.03 at all levels of CV95 in all the models. 
For bigger batch sizes there was no effect in Robustness for batch size. See discussion for detailed 
explanation. 
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most powerful test, followed by TDT, CI and f2. These results were very similar 
regardless of the T85 of the Reference used in the simulations (Figure 4.8. A-B). 
Analogous results were obtained under the other models for differences in single 
parameters (Figure 4.7 B-D). The magnitude of the differences detected for single 
parameters under all the models are summarized in Table 4.2. 
Again, for conditions of high variability (CV95 ≥ 0.2) PT was the only test in which the 
statistical power and robustness are not so severely compromised due to an increase in 
variability (Figure 4.8.C). 
The capacity of the tests to detect simultaneous differences in more than one parameter 
(Power) is shown in figure 4.9, In this Power contour plots, two parameters are varied 
simultaneously (X and Y axis) and the combination of differences in these parameters 
required by each test to reach a power ≥ 0.8 is represented by a point on the contour 
plot. More powerful tests are able to detect smaller combination of differences with a 
power ≥ 0.8 (points closer to the origin on the diagram). Again, in these cases, PT was 
the most powerful test, detecting the smallest combination of differences (Points closer 
to the origin of the contour plots) of the parameters studied, followed by TDT, CI and 
finally f2 under all the models employed, highlighting that in the Peppas model, TDT and 
CI have very similar statistical power.  
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Figure 4.7. Power Comparison of the presented tests. In A (Higuchi Model), Percentage of 
rejections (Power) Vs Difference (%) in bTest according to equation 3 bReference was set at 9 (T85 ≈ 90 
mins) and bTest varying from 7(T85 ≈ 150 mins) to 11 (T85 ≈ 60 mins). In B (Hill Model), Percentage of 
rejections (Power) Vs Difference (%) in t50_test according to equation 4 t50-Reference was set at 1.605 h 
and nReference at 1.85 (T85 ≈ 240 mins) and t50-Test varying from 1.605 to 2.3554 h (T85 ≈ 240 mins to 
T85 ≈ 360 mins). For Peppas Model (C), Percentage of rejections (Power) Vs Difference (%) in kd-Test , 
according to equation 5, kr-Reference was set at 0.6 and kd-Reference at 4.4 (T85 ≈ 130 mins) and kd-Test 
varying from 4.4 to 6.5 (T85 ≈ 130 mins to T85 ≈ 90 mins). For Hill Model (D), Percentage of rejections 
(Power) Vs Difference (%) in t50-Test , according to equation 7, t50-Reference was set at 1.605 h and 
nReference at 1.85 (T85 ≈ 240 mins) and t50-Test varying from 1.605 to 3.405 h, (T85 ≈ 160 to T85 ≈ 520 
mins).  
Two New, Nonparametric Test for Statistical Comparison of Dissolution Profiles 
______________________________________________________________________________ 
39 
 
Figure 4.8. Power comparisson of the presented (Higuchi model). A and B present data from 
typical variability conditions (CV95 =0.1) form Reference formulations with different T85. According to 
equation 3, in A bReference was seted at 9 (T85 ≈ 90 mins) and bTest varying from 7(T85 ≈ 150 mins) to 
11 (T85 ≈ 60 mins). In B bReference was seted at 7 (T85 ≈ 150 mins) and bTest varying from 5 (T85 ≈ 300 
mins) to 9 (T85 ≈ 90 mins). In C condtions are equal to B but in high variability conditions (CV95 
=0.2).  
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Table 4.2. Detectable differences in single parameters with each test. For each paramater of 
each model, the minimum detectable difference (in percentage of the parameter) for each test (with 
power ≥ 0.8) is presented, the correspondent difference in t85 produced by the difference in the 
parameter is also displayed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Consistent with the results for robustness, the power of the CI and TDT tests under high  
variability conditions was rather poor, f2 performance was slightly better but still not 
acceptable, and PT showed the best performance in this scenario although its power 
was significantly decreased compared to low variability conditions (Figure 4.9). 
The demand for a very powerful and robust statistical tool, able to detect small 
differences in dissolution profiles can be satisfied with the introduced PT. PT was able 
to detect with statistical power ≥0.8 the smallest differences in each model parameters, 
 
Model 
 
 
Parameter 
 
 
f2 
 
 
CI 
 
 
TDT 
 
 
PT 
 
Higuchi b 16.6% 14.4% 12.22% 6.6% 
 t85 44% 35% 27.77% 10% 
Korsmeyer n 9% 6.75% 6.5% 2.75% 
 t85 33% 28.32% 27.53% 12.25% 
 k 16.6% 14.4% 12.22% 6.6% 
 t85 44% 35% 27.77% 10% 
Peppas Kd 40.91% 29.55% 27.27% 15.90% 
 t85 23.08% 17.36% 16.15% 9.81% 
 Kr 43.75% 34.37% 36.46% 16.6% 
 t85 25.47% 21.17% 22.17% 11.54% 
Weibull a 39.17% 30% 20.83% 14.17% 
 t85 35.64% 29.52% 22.3% 16.19% 
 B 10% 7.67% 6% 3.67% 
 t85 39.51% 32.55% 26.87% 17.76% 
Hilll T50 34.57% 29.90% 20.55% 7.13% 
 t85 38.33% 32.91% 25% 10% 
 n 86.5% 81.1% 43.24% 10.8% 
 t85 33.5% 31.66% 22.08% 5% 
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normally more than two times smaller than the differences detected with the same 
power with f2 (Table 4.1). For example, in Korsmeyer model, PT was able to detect 
differences of 4% in the kinetic constant while f2 is able to detect just differences 
greater than 20%, this can represent a 10% detectable difference in T85 with PT 
against a 40% detectable difference in T85 with f2. 
 As we have shown, PT can be used to compare profiles even with high levels of 
variation, moreover, PT allows the user to choose the level of statistical uncertainty. 
Furthermore, this test is not especially sensitive to the sample size employed in the 
comparisons, provided that the sample size is greater than n = 3 (due to the 
permutation nature of PT, the sample size of n = 3 highly compromised the power of the 
test and should not be employed). A sample size of n = 6 could be used without 
significantly altering its good performance compared to a sample size of n = 12. PT 
appears ideal for situations in which high similarity should be proven, e.g., in cases of 
drugs with a narrow therapeutic window, or with low permeability and/or solubility or 
susceptible of intestinal transport or metabolism, and currently there is no test as 
powerful and robust that can do so with similar statistical consistency.  
 
4.4.4.  Flexibility of TDT  
As previously mentioned, in some situations, however, detection of significant but small 
differences in dissolution profiles may not be the objective and a more tolerant and 
flexible test is needed. This flexibility to vary the tolerated in order to detect larger or 
smaller differences in dissolution profiles is precisely one of the designed properties of 
the TDT test. 
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Figure 4.9. Bidirectional power exploration of the tests. Contour plots of power ≥ 0.8 for the 
tests. The combination of differences in two parameters required by each test to reach a power ≥ 0.8 
is represented by a point in the contour plot. In A (Korsmayer Model), according to equation 4. 
kReference was set at 7.5 and nReference at 0.5 (T85 ≈ 130 mins) and kTest and nTest varying from 7.5 to 8.2 
and 0.5 to 0.54 respectively (T85 ≈ 150 mins to T85 ≈ 65 mins). For Peppas Model (B), according to 
equation 5, kr-Reference was set at 0.6 and kd-Reference at 4.4 (T85 ≈ 130 mins) and kr-Test kd-Test varying 
from 0.6 to 0.8 and 4.4 to 6 respectively (T85 ≈ 130 mins to T85 ≈ 80 mins). For Weibull Model (C), 
according equation 6, BReference was set at 0.75 and kd-Reference at 0.03 (T85 ≈ 250 mins) and kd-Test and 
BTest varying from 0.03 to 0.045 and 0.75 to 0.82 respectively (T85 ≈ 250 mins to T85 ≈ 120 mins). In 
D (Hill Model), according to equation 7. t50-Reference was set at 1.605 h and nReference at 1.85 (T85 ≈ 240 
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mins) and t50-Test varying from 1.605 to 3.405 h, and nTest varying from 1.85 to 3 (T85 ≈ 160 to T85 ≈ 
520 mins).  
 
Flexibility of TDT is shown for TDT in Figure 4.10 in which TDT with  and  are 
compared to f2. It can be appreciated that increasing the value of  decreases the 
power of the test, in this particular case TDT with  was more powerful than f2, 
while TDT with  was less powerful than f2.  
In addition TDT takes into account information on every tablet at every single point and 
does not rely on measures of central tendency as do f2, CI and PT, therefore, the 
analysis it provides may be more comprehensive than those of the other tests.  
 
4.4.5.  Effect of Independence and Sample Size on Power 
AS previously stated, the underlying principle of the TDT demands that the data from 
every time point of every tablet be independent and identically distributed (iid-
conditions). Effects of iid-conditions were analyzed and compared with no-iid conditions 
to determine how necessary iid-conditions are to a proper performance of the test. The 
effect of iid was shown to be of no practical importance because, in all the cases and 
models studied, the differences in power between iid and no-iid conditions were typically 
less or equal to 5% (Figure 4.1 and Table 4.3). In principle, the TDT test will perform 
similarly under no-iid conditions or iid-conditions and the former may be preferred for 
convenience (a smaller number of tablets is needed).  
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Figure 4.10. Flexibility of TDT. Power Comparison of f2 and TDT with two different values of  . For 
Peppas Model, according to equation 5, kr-Reference was set at 0.6 and kd-Reference at 4.4 (T85 ≈ 130 mins) 
and kr-Test kd-Test varying from 0.6 to 0.8 and 4.4 to 6 respectively (T85 ≈ 130 mins to T85 ≈ 80 mins. 
 
Although iid-conditions had a minor effect on the power of the three tests, this did not 
alter the relative power of the tests (TDT-1 > f2 > TDT-2) in any of the studied models. 
The robustness of TDT for  was good and even better for higher values of  . 
The effect of sample size on the power of the tests is also summarized in table 4.3 for 
each test and each dissolution model; in general, smaller sample sizes reduced the 
power of PT and TDT and increase the power of CI and f2. According to standard 
statistical theory, the power of a test increase with sample size and should not be 
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increased by reduction in sample size as happened with f2 and CI in these simulations, 
it shows the limitations of the f2 similarity factor. 
 
 
 
Figure 4.11. Effect of iid-conditions on DPC-tests Power. Power Comparison of f2 and TDT with 
two different values of   under iid and no-iid conditions under Weibull model. according to equation 6, 
BReference was set at 0.75 and aReference at 0.03 (T85 ≈ 250 mins) and aTest and BTest varying from 0.03 to 
0.045 and 0.75 to 0.82 respectively (T85 ≈ 250 mins to T85 ≈ 120 mins) 
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Table 4.3. Effect of iid-conditions and sample size in statistical power for all the tests. 
    Test & 
              Condition 
Model 
f2 
iid 
CI 
iid 
TDT 
iid 
PT 
iid 
F2 
S.S.S. 
CI 
S.S.S 
TDT 
S.S.S. 
PT 
S.S.S. 
         
Higuchi ( )  - - ( )* + + + - - -** 
Korsmeyer - - f + + + + - - -** 
Peppas ( ) - f + f ( ) - -** 
Weibull ( ) ( ) ( ) ( ) ( ) + - -** 
Hill ( ) ( ) ( ) ( ) ( ) + - -** 
iid  : Independent identically distributed. 
S.S.S. : Smaller Sample Size 
+   :  Slight increase in Power     
+ +  : Evident increase in Power 
-   : Slight decrease in Power    
- -  : Evident decrease in Power  
( )  : No apparent effect     
f   : Fluctuating. A different effect (slightly increase or decrease) at different zones of the diagrams 
-*For batch size = 3, level of rejections of PT remain at 0.03 at all values of the test parameters, it is 
not and effect of batch size in general but of this very small batch size in particular. 
 
 
4.4.6. Time Sample Strategies  
Figure 4.7 B and C show some apparent discontinuities in the power curves of f2, CI 
and TDT tests. For example, in Figure 4.7 B for nReference = 0.5, the power of f2, CI and 
TDT first increases continuously at increasing values of nTest (Korsmeyer model), but at 
nTest = 0.5275 (difference of 5.25%) the power of the three tests is reduced. This 
unexpected phenomenon was identified as an artifact due to sampling times. The time 
sampling scheme was designed to be as realistic as possible (intervals of 5, 10, 15, 20, 
or 30 min. see section 4.3.2.3). According to this rules, solving equation 5 for nTest = 
0.52625, t85=100.8161, samples must be collected at 6 time points (20,40,60,80,100 
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and 120 min), in contrast, when nTest = 0.5275, t85 is 99.72 and just 5 time points need to 
be sampled (20,40,60,80 and 100 min). This reduction in the number of sampling time 
points can produce a 50% decrease in power in the f2, CI and TDT tests. To counteract 
this effect, an optimized sampling scheme was developed. In optimized sampling, the 
number of time points is fixed, and t85 (the smaller between Reference and Test) is 
divided into equidistant time points with t85 as the last time point, for example, fixing 6 
time points for a t85 = 95 min, the time points are: 15.833, 31.667, 47.5, 63.333, 79.167 
and 95 min. Optimized sampling with 6 and 5 points, respectively, was employed in the 
analysis (Figure 4.12). In either case of such optimized sampling the discontinuity in 
power was no longer present.  
No significant difference was found between results obtained using 5 or 6 time points, 
confirming that the apparent discontinuity is due to the sampling strategy and not to the 
number of time points sampled. These finding suggest that optimized sampling should 
be employed as a first option for dissolution profile comparisons. 
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Figure 4.12. Effect of time sampling strategy on statistical power (Korsmeyer model). Power 
Comparison of f2, CI and TDT with three different sampling schemes at typical variability conditions 
(CV95 =0.1). According to equation 3, kReference was set at 7 and nReference at 0.5 (T85 ≈ 150 mins) and 
kTest varying from 7.5 to 8.2 and nTest fixed at 0.5. 
 
 
 
 
 
Two New, Nonparametric Test for Statistical Comparison of Dissolution Profiles 
______________________________________________________________________________ 
49 
4.4.7. Experimental Design Driven Strategy for Performing Optimal 
Dissolution Profile Comparisons 
 
Combining the information presented here with basic principles of experimental design, 
we propose an experimental design driven strategy for performing optimal dissolution 
profile comparisons; this strategy is illustrated in Figure 4.13.  
 If the goal is to detect small differences (Table 4.2) in dissolution profiles, PT 
must be employed with a sample size greater or equal to n = 6 and a standard 
time sampling can be employed.  
 If a less strict comparison is needed or if there is no certainty about the degree of 
similarity that can be accepted, the following procedure should be followed: 
o Preliminary experiments must be conducted to determine the t85 of the 
Reference and Test formulations and to fit the dissolution data to one or 
several models, (including models not presented in this work).  
o The minimum detectable difference (the difference to be considered as not 
similarity), must be determined either, by finding the adequate difference 
at t85 or t50 (time at which 50% of the labeled drug is dissolved) or a 
combination of both, or ideally, through either an IVIVC model [72] 
indicating the differences in dissolution that may lead to differences in 
bioavailability, [73] or by fitting the dissolution data for preliminary 
experiments to available dissolution models [30], [74-76] and estimating 
the difference in parameters acceptable as similar. This step is the most 
complicated and the most susceptible to produce under- or over-
estimation of the detectable difference due to personal interpretation. 
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o After the acceptable difference is determined and the dissolution model 
selected, simulations with TDT must be done to determine the value of  
and sample size at which the determined minimal difference in parameters 
or t85 or possible combinations is detected with an acceptable statistical 
power (power of 0.8 or higher is recommended) always using an 
optimized time sampling strategy.  
o Preferably, effects of iid-conditions on variability, robustness and power of 
TDT should be addressed in simulation or laboratory experiments. 
o Finally, the dissolution assays must be performed under the conditions 
(iid/no-iid-conditions,  and sample size) found and the statistical 
comparison must be done using TDT. 
In this way the flexibility of TDT is used to customize a comparison test (setting a 
specific  value) able to detect the differences in dissolution that can produce a 
difference in the bioavailability/bioequivalence of the formulations. The procedure 
described may seem arduous compared to the current f2 standard, however, it follows 
the typical procedure employed in any experimental design aimed at detecting 
significant differences with a quantified statistical uncertainty and known type-I and 
type-II errors. The procedure involves the following steps: i)preliminary data analysis, 
ii)determination of minimum detectable acceptable difference, iii)determination of 
sample size according to a desired level of power and robustness and 
iv)experimentation and statistical computation. 
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Figure 4.13. Experimental Design Driven Strategy to Perform Optimal Dissolution Profile 
Comparisons. Diagram flow of the proposed strategy to Perform Optimal Dissolution Profile 
Comparisons, Each stage of the presented strategy corresponds to a stage of a typical experimental 
design lustrated in the right. 
 
Due to the simulated nature of the data presented here, experimental verification of the 
lack of effect for iid-conditions and examples of how to customize TDT with specific 
formulations are recommendable. Also, evaluation of additional available expressions 
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for modeling drug dissolution [74], including models for controlled released mechanisms 
[75, 76] might be an obvious subject for future studies.  
 
 
4.5. Conclusions  
Two new statistical tests, the permutation test (PT) and the tolerated difference test 
(TDT), are presented for dissolution profile comparison in which type-I and type-II errors 
can be quantified, and have a stronger statistical basis than the current alternatives 
(e.g., the f2 similarity factor). The two new tests showed acceptable robustness at 
standard conditions of variation (CV95 ≤ 0.1). PT was the most robust and powerful test 
in all the conditions studied (even in conditions of high variability CV95 ≤ 0.2 and reduced 
sample sizes). This test is strongly recommended for identifying small differences in 
dissolution. For  , TDT showed good robustness and very good power in all the 
conditions studied.  
The impact of iid-conditions in TDT was not particularly large, therefore the more usual 
no-iid conditions could be employed (experimental confirmation of this is still pending). 
The possibility to modify the value of  confers great versatility on TDT and allows it to 
be customized for any specific formulation. To make the best use of the two new tests, 
a strategy to design and perform a dissolution profile comparison is presented under 
typical premises of statistical experimental design. Finally, it was shown that optimized 
time sampling should be employed when possible to avoid artificial discontinuities in the 
statistical power of the tests, except for PT which is not susceptible to this effect. 
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5. Tailor-Made DPC-tests for comparing ER Formulations 
Using IVIVC Models 
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5.1. Abstract 
Current procedures for performing dissolution profile comparisons are restricted to 
mathematical distances (such as the f2 similarity factor) in which limits for declaring 
similarity or non-similarity are fixed, drug-unspecific and not based on any 
biopharmaceutical criteria. This problem and the lack of strong statistical basis, hinder 
the application of DPC-tests for evaluating similarity of ER formulations. This study 
aimed to develop drug-specific DPC-tests, able to detect differences in release profiles 
between ER formulations that represent a lack of BE. Dissolution profiles of Test 
formulations were simulated using the Weibull and Hill models. Differential equations 
based in vivo-in vitro correlation (IVIVC) models were used to simulate plasma 
concentrations. BE trial simulations were employed to find the formulations likely to be 
declared bioequivalent and nonbioequivalent (BE-space). Customization of DPC-tests 
was made by adjusting the delta of the tolerated difference test (TDT) described in the 
previous chapter. This delta value was tailored for three ER formulations (3.6 for 
metformin, 5.95 for diltiazem and 3.45 for pramipexole) to detect with a statistical power 
≥ 80%, differences in release profiles identified as biorelevant limits 
(nonbioequivalence). The Impact of the dissolution profile comparisons  conditions, BE-
trial conditions, and drug properties in the determination of biorelevant limits were 
investigated. The other described DPC-test, the permutation test (PT), showed excellent 
statistical power. All the formulations declared as similar with PT were also 
bioequivalent. Similar case-specific studies may support the biowaiving of ER drug 
formulations based on customized DPC-tests. 
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5.2. Introduction 
The pharmaceutical industry is constantly searching for effective surrogates for judging 
therapeutic equivalence of pharmaceutically equivalent drug products. One widely 
accepted and official procedure to ensure efficacy and safety of new formulations is the 
assessment of BE, in which it an absence of significant differences in the rate and 
extent to which the active ingredient become available at the site of drug action must be 
demonstrated [4-9]. 
In cases where the excipients of a formulation do not affect the absorption of the active 
pharmaceutical ingredient (API), the API is not a prodrug, does not have a narrow 
therapeutic index and is not intended to be absorbed in the oral cavity, in vitro testing 
has been accepted as a sufficiently reliable surrogate for an in vivo BE study [10, 11]. 
The regulatory acceptance of in vitro testing as a reliable surrogate for an in vivo BE is 
referred as “biowaiver” [10, 11]. 
Requirements for granting a biowaiver of an in vivo BE study depend on the type of 
drug, type of formulation, the type of post-approval change and the information 
available. For IR solid oral dosage forms of BCS class I drugs (highly permeable and 
soluble), demonstration of ≥ 85% dissolution in one or several media in 15 min is 
normally enough for conceding a biowaiving of BE studies in the case of post-approval 
changes of minimal impact [11]. Debate is still open as to whether biowaiving could be 
accepted for IR formulations of other BCS class drugs and guidelines differ in this point 
[10].  
The therapeutic equivalence of drug formulations is assured by in vitro comparison of 
dissolution profiles. The term similarity has been employed to describe the lack of 
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difference between dissolution profiles from two different sources (formulations) and it is 
normally established by using the f2 similarity factor [2, 19, 41, 42]. In order to grant a 
biowaiver for ER formulations or for higher impact changes [1] in IR formulations, 
guidelines normally demand that similarity of profiles is demonstrated through the f2 
similarity factor (equation 8). Additionally, in the case of ER, a validated IVIVC model 
must be available. However, the limits of rejection of f2 (≤ 50) are not justified by any 
mechanistic or biopharmaceutical reasons. As it is an empirical and fixed limit, it is 
unlikely to exhibit the specific discriminatory power required in all scenarios in which it is 
currently used. Moreover, recent publications have stated that on the one hand, f2 may 
classify formulations that are nonbioequivalent as similar [30, 44], while on the other 
hand f2 can also be over-discriminative in some cases [32, 70, 77]. Additionally, several 
publications have recognized some major statistical and conceptual limitations of f2, 
including, uncertain level of confidence, low statistical power, lack of biopharmaceutical 
or statistical reasons, lack of flexibility to perform in different scenarios and poor 
statistical consistency [30, 43, 44, 77, 78]. 
This rigidity of f2, being too restrictive in some cases and too liberal in others, ratifies 
that dissolution tests are only physical tests until they are linked to in vivo performance 
of the formulations tested [28, 79], and further highlights the need to identify dissolution 
limits which ensure clinical quality for each particular case [32]. Advances in developing 
more biorelevant dissolution methodologies are continuously being made [21-27], and 
have been identified as a major priority [28, 29]. However, statistical tools to compare 
dissolution profiles have not been improved in the last years, despite the fact that a 
more rigorous application of statistics to understand and incorporate variability and 
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uncertainty has also been identified as a priority in order to achieve a better integration 
of biopharmaceutics and quality for patient benefit. [80]. 
It was described in the previous chapter a new strategy to perform case-by-case 
dissolution profile comparisons [78], including two new statistical tests for comparing 
drug dissolution profiles; the PT, a very powerful and strict test to confer similarity, and 
the TDT, a flexible test in which the limits of rejection can be varied according to a 
desired level of tolerance without affecting its statistical properties. These two tests 
have the advantage of a better uncertainty quantification (Type I and Type II errors) and 
better statistical consistency of their estimators.  
Using validated IVIVC models, plasma concentrations achieved by different 
formulations can be simulated from their dissolution profiles [72, 81, 82]. It is further 
possible using such models, to find what difference in dissolution, or in other words 
which formulations are likely to produce differences in-vivo large enough to be 
considered as nonbioequivalent [83]. We can then customize DPC-tests to declare non-
similarity at levels of dissolution differences at which nonbioequivalence is expected.  
This study aimed first, to develop drug-specific DPC-tests for three ER formulations 
(metformin, diltiazem and pramipexole) using IVIVC models, computer simulated BE 
trials and permutation tests. These customized tests should be able to detect, at a 
known level of certainty, differences in release profiles between ER formulations that 
represent a lack of BE. Secondly, we aimed to investigate the effect of Dissolution 
Profile comparisons conditions, BE-trial conditions, and drug/formulation properties in 
the determination of biorelevant limits. 
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5.3. Methods 
5.3.1. General Strategy 
The strategy used to identify bioequivalent and nonbioequivalent formulations is 
illustrated in Figure 5.1 taking pramipexole as example. In-vitro dissolution profiles 
were simulated for several formulations by modifying the Weibull model parameters and 
PK profiles of the formulations were generated using IVIVC models. Through BE 
simulation studies, nonbioequivalent formulations were detected. Once the BE-spaces 
were delimited, TDT a DPC-test, was customized to declare as non-similar, the 
formulations that were likely to be nonbioequivalent. The strategy used to investigate 
the effect of drug/formulation properties was similar (Figure 5.2). Starting with the 
same dissolution profile different PK profiles can be generated by varying the IVIVC 
model input parameters. Investigation of the effect of such variation on the BE-space for 
the theoretical drug is then possible. 
 
5.3.2. In Vitro-In Vivo Correlation Models (IVIVC models) 
Two published differential-equation-based IVIVC models were used for analysis. For 
diltiazem and metformin (Figure 5.3.a), a one compartment pharmacokinetic model with 
a first order rate elimination was employed for describing plasma concentrations in 
which the rate of in-vivo input is connected to the rate of in-vitro dissolution through a 
functional dependency that allows inclusion of time scaling, time shifting and absorption 
window [52].  
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Figure 5.1. General strategy used to build the BE-spaces. 
 
 ( )       ( )        (      ) equation 12 
Where    is the time-scaling factor,    is the scaling factor,      is the dissolution rate 
and     ( ) accounts for the variability of the in-vivo absorption as the drug moves 
along the gastrointestinal tract, including a truncated absorption at time      : 
    ( )  
   (      )
     (      )
  equation 13 
The dissolution rate (    ) was described by the Hill function [39] described in equation 7 
Of which the differential expression is:  
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    ( )   
     
  
  
         
     
(   
     ) 
 equation 14 
Where     ( ) is the fraction (%) of drug released at time  ,     is the time at which 50% 
of the drug is released from the formulation and   is a shape parameter. Data were 
generated to reproduce the data of Gillespie [84] for diltiazem and the data of Balan and 
co-workers [85] for metformin. 
 
Figure 5.2. strategy used to investigate the effect of drug/formulation properties) on the 
determination of equivalent formulations. Starting with the same dissolution profile different PK 
profiles can be generated by varying the IVIVC model input parameters. 
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Figure 5.3. Schematic representation of the biopharmaceutic/pharmacokinetic models for 
the IVIVC of dialtiazem and metformin (a) and pramipexole (b). 
 
For pramipexole (Figure 5.3.b), a two compartments model with first order absorption 
and elimination was used for describing plasma concentrations [53], in which the 
dissolution rate was described by the Weibull function described in equation 6 [36-38] of 
which differential expression is: 
    ( )   
     
  
             (   )      (     )
 
  equation 15 
Where     ( ) is the fraction (%) of drug released at time  ,    is the dissolution constant 
and   is the shape parameter. The relationship between the           and            
was modeled by                             where      is a scale factor representing 
Tailor-Made DPC-tests for comparing ER Formulations Using IVIVC Models 
______________________________________________________________________________ 
62 
the increment in the in-vivo dissolution.      of        (         )was used in all 
simulations. 
For the purpose of this study only differential equations-based IVIVC methods were 
included, because of the more mechanistic nature of these models [29, 86, 87]. All 
parameters employed are listed in Table 5.1. 
 
Table 5.1. Population pharmacokinetic models parameters used in the IVIVC models.  
 Pramipexole I Diltiazem Metformin 
BCS I I III 
Kel (h
-1) 0.087 (13) 0.138 (10) 0.23 (10) 
tlag (h) 0.22 (66.3) 0.57 (10) 0.86 (10) 
tcut (h) NA 6.36 (20) 4.77 (20) 
Ka (h
-1) 5.26 (91.8) NA NA 
V1 (L) 351 (14.1) NA NA 
V2 (L) 60.9 (10) NA NA 
CLD (L/h) 33.2 (10) NA NA 
Parameters are listed with the IIV in parenthesis. Kel, elimination constant; tlag, lag time; tcut, 
absorption window; Ka, absorption constant; V1, V2, volumes of distribution in the central and 
peripheral compartments respectively. CLD, Apparent distribution clearance, NA: Parameter not used 
in that model. 
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5.3.3. Test and Reference Formulations 
Reference formulations were modeled as follows: 
Metformin:             ;        (Hill Model, equation 7) 
Diltiazem:            ;          (Hill Model, equation 7) 
Pramipexole:             ;          (Weibull Model, equation 6) 
Test formulations were generated by varying simultaneously the two dissolution model 
parameters (t50 and n or    and  ) from -95% to 200% around those of the Reference 
formulation. Variability (CV 10%) was included at all dissolution points to mimic 
experimental data. 
 
5.3.4. Simulations and Bioequivalent Studies 
Simulations of plasma concentration were conducted in the R software environment 
(version 2.14.2. R Development core Team 2013) using the models detailed in the 
previous section. Inter individual variability (IIV) was include for each parameter (Table 
5.1) to fit the reported experimental variability [52, 53] including an overall CV of area 
under the curve (AUC)0-∞ and Cmax of 15%. In total, 1000 BE crossover simulated 
studies per scenario were conducted. In each study, 12 healthy volunteers were 
generated by Monte Carlo simulations. Each volunteer received an oral dose of the Test 
and Reference formulation with a wash-out period between the administrations. AUC0-∞ 
and maximum plasma concentration (Cmax) were calculated from the generated plasma 
concentrations. BE between formulations was determined by calculating 90% 
confidence intervals (90%CI) of the ratio between Test and Reference means after log-
transformation of AUC0-∞ and Cmax. The formulations were considered bioequivalent if 
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the 90%CI of AUC0-∞ and Cmax ratios were contained within the acceptance interval of 
80.00 – 125.00%. 
 
5.3.5. Dissolution Profile Comparisons Tests (DPC-tests) 
Dissolution profiles from the Reference and Test formulations were compared using the 
f2 similarity factor (Equation 7) and two recently described tests, PT and TDT [78]. As 
described in section 4.3.3. 
 
5.3.6. Statistical Power Explorations 
Sets of 12 Reference formulation tablets and 12 Test formulations tablets were 
generated under conditions of non-similarity, when different model parameters were 
employed for the Reference and Test formulations. Each pair of batches was compared 
using f2, TDT and PT. At every condition, 5000 sets of Reference-Test were generated 
and the percentage of rejections (%detections of no similarity) was evaluated. More 
powerful tests are expected to detect smaller differences in the parameters used. In all 
cases equidistant sample points were sampled from which the last sample point was the 
smaller t85 (time to reach 85% release) of the two formulations. 
 
5.4. Results 
5.4.1. Illustrative Example 
In Figure 5.1.b, results from pramipexole are outlined as an example. Test-1 is 
bioequivalent to the Reference formulation by AUC and Cmax. Formulation Test-2 is 
bioequivalent to the Reference formulation by AUC but not by Cmax and formulation 
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Test-3 is not bioequivalent to the Reference formulation by either AUC or Cmax. The BE-
space delimits the bioequivalent formulations from the nonbioequivalent. TDT was 
customized to declare as non-similar, formulations that are likely to be 
nonbioequivalent. To investigate the effect of drug/formulation properties the same 
dissolution profile (Test-1) was employed. Different PK profiles can be generated by 
varying the IVIVC model input parameters. In Figure 5.2, using the same Test 
formulation (equal kd and β), two different PK profiles are generated by using different 
Ka values. The Cmax BE-space for the theoretical drug with a smaller ka was reduced 
(yellow BE-space) and the Test formulation is no longer bioequivalent to the Reference 
formulation by Cmax. When the larger ka is used the same Test formulation is 
bioequivalent to the Reference formulation (inside the red BE-space). 
 
5.4.2. Bioequivalent and Similarity Spaces 
For each drug, Test formulations were compared to the Reference formulation in their 
dissolution profiles and plasma levels. Figure 5.4 illustrates the effect of dissolution 
parameters on BE and similarity. The X and Y axes show the difference in each one of 
the dissolution parameters of the Test formulation compared to the Reference 
formulation. When the difference in the two parameters is zero (coordinates 0,0 in the 
contour plots) the Test and Reference formulations are the same. Response surfaces 
for AUC and Cmax display the Test formulations (combination of dissolution parameters) 
with probability ≥ 80% of being nonbioequivalent by AUC or Cmax respectively. Density 
contour plots displaying probability of rejection from 0 to 100% for AUC and Cmax are 
shown in the annexes (A.2-A.7). Response surfaces for f2 and PT delimit the 
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combination of dissolution parameters at which the probability of declaring non-
similarity, using the corresponding test, is ≥ 80% (Sim-space). 
 
Figure 5.4. BE-Spaces of the three formulations. Contour lines for AUC and Cmax display the Test 
formulations (combination of dissolution parameters) with probability ≥ 80% of being declaring 
nonbioequivalent by AUC or Cmax respectively. Striped zones display the nonbioequivalent formulations 
declared as similar with f2. a) Metformin, b) Diltiazem and c) Pramipexole 
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PT was the most powerful test to declare as non-similar, Test formulations with changes 
in the dissolution model parameters compared to those of the Reference formulation. 
Consequently, formulations declared as similar with PT were always also bioequivalent 
and differences in Cmax and AUC from the Test and Reference formulations were less 
than 1.5%. For all three drugs, f2 showed less power than PT, and several formulations 
declared as similar with f2 were not bioequivalent.  
 
5.4.3. Customization of TDT 
Dissolution profiles of the generated formulations were compared using TDT at different 
values of . Figure 5.5 shows the different similarity space (Sim-space) of TDT at 
increasing values of  for the pramipexole formulation. A  of 3.45 is the maximum  at 
which all the formulations declared as similar with this test are also bioequivalent. A  of 
3.6 for metformin and 5.95 for diltiazem were found following the same procedure (A.8-
A.9). This  value represents the average tolerated difference (in %) between two 
formulations at any time point to produce bio-equivalent formulations under both criteria, 
AUC and Cmax. 
 
5.4.4. Effect of Drug & Formulation 
The effect of changes in ka, kel (CL), t-lag, V1, V2 and CLD (model II in Figure 5.3) on the 
BE-space of the pramipexole formulation was studied. Changes in V1, V2 and CLD of 
ten-fold had no effect on the BE-space (A.10). Changes in ka of 10-fold had no 
apparent effect on the BE-space of AUC or Cmax.  
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Reductions in ka of 50 fold or bigger showed an increasing reduction in the BE-space of 
Cmax (Figure 5.6.a). Changes in t-lag had a direct impact in the BE-space of both AUC 
and Cmax (Figure 5.6.b-c), when t-lag was not considered (t-lag =0) the BE-space was 
increased. For a t-lag of 2 hours, the BE-space was reduced to 25% of the original area. 
Changes in Kel had no effect on the BE-space of AUC. A slight effect in the BE-space of 
Cmax by changes in kel was observed, however, there was no change in the total area of 
the BE-space (less than 5%), but a small modification in the shape, regardless if the kel 
was increased or decreased. The same effect was observed for metformin and 
diltiazem (A.11-A.12). Studied effects are summarized in Table 5.2. 
 
Figure 5.5. Customization of TDT. Sim-Spaces of TDT at different values of . for pramipexole 
formulations. 
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Table 5.2. Effect of volunteers sample size and drug parameters on the BE-space  
 Pramipexole Diltiazem Metformin 
 AUC Cmax AUC Cmax AUC Cmax 
Increase sample size (volunteers) ↑ ↑ ↑ ↑ ↑ ↑ 
Change Kel ↔ ↑ ↓ ↔ ↑ ↓ ↔ ↑ ↓ 
Increase t-lag ↓ ↓ NA NA NA NA 
Reduce ka ↔ ↓ NA 
NA NA NA 
Change V1 ↔ ↔ 
NA NA NA NA 
Change V2 
↔ ↔ NA NA NA NA 
Change CLD 
↔ ↔ NA NA NA NA 
↑: Increase BE space; ↓: Reduce BE Space; ↑↓: Change BE space, some zones are augmented and 
some are reduced but no total increase or decrease; ↔ : No apparent effect; NA: Parameter not used 
in that model. 
 
and c) effect of tlag on Cmax BE-Space. 
 
5.4.5. Effect of BE trials Conditions and DPC-tests Conditions on BE-
space and Sim-space 
BE trials simulations were performed with different numbers of patients to study the 
effect of sample size in the BE-space, Figure 5.7.a shows the increment in the BE-
space, in both AUC and Cmax, at increasing numbers of patients. Nevertheless, the 
increment in the area from 12 to 18 patients was less than 3%, and the reduction in the 
BE-space from 12 to 6 patients was less than 5%. 
The Sim-space was sensitive to the number of points used in the dissolution profile 
comparison, a reduction in Sim-space (increasing statistical power) at higher number of 
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time points was detected (Figure 5.7.b). These effects of number of patients and of time 
points were also observed for the metformin and diltiazem formulations (A.13-A.14).  
 
Figure 5.6. Effect of drug/formulation parameters in the determination of BE-Space. a) effect 
of ka on BE-Spaces, b) effect of tlag on AUC BE-Space, c) effect of tlag. 
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Figure 5.7. Effect of BE trials conditions and DPC-tests conditions on BE-Space and Sim-
Space. a) effect of number of volunteers included in BE-trials on BE-Spaces, b) effect dissolution 
sampled time points on Sim-Space. 
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5.4.6. BE-space Compared to TDT to MDT and MRT 
Mean dissolution time (MDT) and mean residence time (MRT) were calculated for all 
the reference formulations and compared to the BE-space. Surface responses of MDT 
and MRT are depicted in Figure 5.8 for pramipexole formulations. There is no overlap 
between the MDT or MRT response surfaces with the BE-space. Test formulations with 
the same MRT or MDT of the Reference formulation could be nonbioequivalent. 
Likewise, formulations with very different values of MDT and MRT are included in the 
BE-space. Similarly, BE-space did not match with the surface spaces of MDT or MRT 
for metformin or diltiazem (A.15-A.16).  
 
5.5. Discussion 
In this study, using IVIVC models, we aimed to design case-specific DPC-tests which 
were able to identify formulations likely to be bioequivalent in-vivo as in-vitro similar. As 
expected, the differences in dissolution necessary to produce nonbioequivalent 
formulations vary from one drug-formulation to another, depending on the drug and 
formulation. f2 failed to associate the in vitro similarity of two formulations with their 
comparative in-vivo performance in the three cases investigated. Moreover, f2 declared 
as similar not only formulations that are likely to be bioequivalent in vivo, but also 
formulations that are likely to be nonbioequivalent in vivo (Figure 5.4). This observation 
is in agreement with one of the criticisms of f2 [30, 32] of lack of flexibility to perform in a 
wider range of cases. We propose the need to analyze individually each formulation, 
and customize case-specifically, the limits of rejection of DPC-tests based on the type of 
formulation and the drug. 
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Figure 5.8. Comparison of BE-Spaces with a) MDT and b) MRT. 
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TDT is a DPC-test specifically designed to display this desired flexibility, by varying the 
δ value, without compromising its statistical properties (known type I and II errors). We 
were able to associate TDT limits of rejection with an in-vivo property (BE) of the tested 
formulations. Test formulations declared as similar to the Reference formulation using 
this customized DPC-test are expected to be also bioequivalent and consequently to 
retain the same efficacy and safety profile.  
Having a customized DPC-test offers some technological and regulatory advantages; 
From the point of view of the manufacturer, once a DPC-test is customized, dissolution 
profile similarity can be used as a critical quality attribute (CQA) [88], for routine quality 
control, as a tool for post-approval changes, or to assure quality consistence of the 
same formulation manufactured in a new facility [88, 89].  
From the regulatory point of view, an established DPC-test of an innovator formulation 
represents a fast, cheap and reliable protocol with clear acceptance criteria to test new 
generic formulations, reducing the costs and time of these submissions and potentially 
avoiding unnecessary in-vivo BE studies. 
PT was the most restrictive test to confer similarity of dissolution profiles, typically, 
formulations declared as similar with this test did not differ in AUC and Cmax more than 
1.5% assuming the same patient with no intra-occasion variability. PT should be a more 
suitable test for monitoring similarity as a CQA because it would be more sensitive to 
detect CQA changes. 
Ideally, all the bioequivalent formulations should be declared as similar, however, a total 
overlap of the BE-space and the Sim-space was not achieved with the investigated 
tests. Nevertheless, according to risk management principles [80, 90], the reduction of 
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risk caused to patients by declaring as similar formulations that are not bioequivalent, 
must be considered as a higher priority than reducing manufacturer risk of declaring as 
non-similar formulations that are bioequivalent. TDT allows maximization (Figure 5.5) 
of the overlap between BE-space and Sim-space without compromising the patient risk.  
It has been stated that ER formulations can produce flip flop-like kinetics when the 
apparent ka < kel (kel/ka ratio > 1), and could lead to miscalculations of the PK 
parameters [91], For pramipexole we observed reductions in the Cmax BE-space for 
values of ka ≤ 0.4 h
-1 (kel/ka ratio = 0.2). Calculating the BE-space for theoretical drugs 
with different kel and ka, the reduction in the Cmax BE-space due to reduction in ka was 
produced only at kel/ka ratios of 0.2 or higher (A.17). This seems to be the limit at which, 
the ka is small enough, in comparison with the kel, to reduce the Cmax in the PK profile. 
This aspect should be accounted for in the design of ER formulations, since a slow 
enough release can have in practical terms the same effect as reducing the ka of the 
drug. We suggest that this flip flop-like phenomenon could be present at kel/ka ratios 
smaller than 1 (i.e. 0.2).  
The BE-spaces of Cmax from the diltiazem and pramipexole (Figure 5.4 and A.2-A.7 ) 
formulations were more affected for changes in the Y axis (shape parameter) than for 
changes in the X axis (speed parameter). It is appropriate to set DPC-tests sensitive to 
changes in the shape parameter because it is related to the release mechanism [28, 
87], and small changes in this in-vitro mechanism may have a larger in-vivo impact.  
For the metformin formulation, the AUC BE-Space and the Cmax BE-space were affected 
by changes in both, the speed and shape parameters, mainly because of the narrow 
absorption window (tcut = 4.77h). The δ value of TDT for this formulation was smaller 
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compared to the one for Diltiazem (Both using the same IVIVC model) supporting the 
concept that DPC-tests to compare formulations of drugs with small absorption windows 
must be very restrictive to declare similarity.  
The δ value of TDT for the metformin formulation (BCS Class III drug with narrow 
absorption window, tcut = 4.77h) was smaller compared to the one for Diltiazem (Both 
using the same IVIVC model), supporting the concept that DPC-tests to compare 
formulations of drugs with small absorption windows must be very restrictive to declare 
similarity. Metformin is a BCS class III drug, experiencing poor bioavailability (40-60%) 
[92, 93] and low permeability in-vivo (2.96-4.5 5 cm-7/s ) [92] and in-vitro (1.4 – 5 cm-7/s) 
[94], this low permeability was included in the model (as smaller S1) and manifested as 
a slower progression (compared to diltiazem a BCS class I) in the plasmatic 
concentration versus percentage of dissolved drug relationship (A.18), reflected not only 
in a larger tmax (4.7 h vs 3.6 h for diltiazem) but also in the fact that the 50% of Cmax in 
plasma is reached only after the 80% of the drug its released (Compared to 45% for 
diltiazem) .  
Absorption is recognized as the rate-limiting step for BCS class III drug formulations [95, 
96], however, for the metformin formulation, test formulations with faster release 
(smaller t50 and larger  ) than the Reference formulation, generated plasma profiles with 
higher Cmax and AUC, resulting in declaration of nonbioequivalence. Formulations with 
slower release (larger t50 and smaller ) were also declared as nonbioequivalent, 
generating plasma profiles with smaller Cmax and AUC. These results indicate that in the 
case of ER products, dissolution may also play a substantial role in the in-vivo 
performance of BCS class III formulations.  
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The input function (equation 12) used in the metformin and diltiazem model, limits the 
potential processes that can be included in the model. For example, differential 
absorption across the GI tract, and concentration-dependent permeability mediated by a 
saturable process have been reported for metformin [92], and cannot be completely 
included in this particular model. However, these effects are not expected to be of high 
relevance in formulations of the same high dose (250 mg), unless the release is 
radically slow, in such case, the PK profile would be restricted more for the short 
absorption window, which is included in the model, than for the effect of saturable 
transport. The customized DPC-test should still be able to declare as similar only 
bioequivalent formulations. Notwithstanding, more mechanistic models, as the one used 
for pramipexole are preferable and necessary to develop in order to increase the 
knowledge of these types of characterizations and formulation comparisons.  
MDT and MRT are statistical moments of the dissolution and PK-profile respectively, 
which have been proposed as predictors of the in-vivo performance of a formulation [72, 
97]. When we compared the surface responses of these moments with the BE-spaces 
(Figure 5.8 and A.15-A.16) we found that MDT and MRT are not useful to discriminate 
between nonbioequivalent and bioequivalent formulations. Nonbioequivalent 
formulations can yield values of MDT and MRT identical or very similar to the MDT and 
MRT of the Reference formulation, and bioequivalent and nonbioequivalent formulations 
can yield the same values of MDT and MRT. We also observed that formulations with 
different MRT yield the same MDT and vice versa (A.19), showing that a correlation of 
these two moments is not possible in the investigated cases. 
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The observed increment in the BE-spaces when the volunteer sample size is 
incremented is in agreement with the fact that due to inter-individual variability, it is 
more likely to declare BE of two formulations when more volunteers are included in a 
BE trial. Likewise, the Sim-space was reduced when the number of time points sampled 
in the dissolutions profiles was increased. These results manifest that conclusions about 
BE or similarity can be affected by the specific setup of each particular comparison. 
Precise limits must be fixed in order to standardize comparisons and rejections criteria. 
Based on these results we propose that a number between 6 and 10 equidistant time 
points must be sampled in the dissolution comparisons, as a good predictor of BE 
studies with 12 individuals. 
The biggest limitation of the introduced case-by-case DCP-tests customizations is that it 
requires a validated IVIVC model for each formulation, and in the case of generic drugs, 
serious harmonization efforts should be made to share these IVIVC models between 
agencies and manufacturers. The computational effort and knowledge required also 
currently impose real constraints on the wide diffusion and implementation of the 
strategy presented here. Besides, it is still questionable which is the most suitable 
procedure to declare BE [13, 98-101] and which other mathematical expressions could 
model drug release more mechanistically [40, 74] .  
The strategy presented in this study of setting limits of rejection of dissolution similarity 
according to probabilities of presenting nonbioequivalence, can be refined, improved 
and applied to other drug-formulations when more IVIVC mechanistic models become 
available. For BCS class III drugs, further studies are required before analyzing the 
possibility of biowaving ER formulations of these drugs [102]. However, we propose that 
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under a deep case-specific analysis, biowaiving of ER of BCS class I drug formulations 
may be possible through customized DPC-tests.  
 
5.6. Conclusions 
In the present study, we have customized a DPC-test for three different ER 
formulations, linking limits of rejection with an in vivo attribute: the high probability of 
being nonbioequivalent. According to these simulations, formulations that can prove to 
be similar with the Reference formulation under the established conditions are likely to 
be bioequivalent. Established conditions were TDT with δ of 3.6, 5.95, and 3.45 for 
metformin, diltiazem and pramipexole respectively and sampling at least six time points 
in the release profiles. Once a specific test is developed for a particular formulation, this 
DPC-test can be used to explore post-approval changes by the manufacturer or to 
evaluate BE between products from different manufacturers, decreasing the need for 
future human BE studies and reducing costs of production. PT was the most powerful 
DPC-test and differences in Cmax and AUC produced by formulations declared as similar 
with PT were less than 1.5% in all cases. Tlag and ka were the drug/formulation 
parameters that influenced BE-space to the greatest degree. For the investigated 
cases, MDT or MRT were not suitable to detect bioequivalent formulations. Similar 
case-specific studies may support the biowaiving of ER drug formulations based on 
customized DPC-test. 
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6. Prediction of Equivalence in a Combined Dissolution and 
Permeation System using customized DPC-tests 
 
 
 
 
 
 
 
The following author contributed to this chapter: José David Gómez-Mantilla, Sandra P. 
Gantzsch, Dominik Selzer, Thorsten Lehr, Ulrich F. Schaefer, Claus- Michael Lehr. 
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 Design, Performance and interpretation of simulations.  
 Construction of the equivalent and similar spaces and customization of the DCP-
test. 
 Design, performance and interpretation of the formulation optimization part.  
 Writing the chapter.  
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6.1. Abstract 
An apparatus for combined determination of dissolution and permeability (d/p-system) 
was previously described by our group and tested with propranolol IR and ER 
formulations. In this study we developed a mathematical model able to predict the 
permeated amount of propranolol from an ER formulation in the d/p-system. After 
considering this propranolol ER formulation as a Reference formulation, we were able to 
predict which dissolution profiles would lead to significant differences in permeability 
compared to the Reference formulation. Formulations that did not lead to significant 
differences in the calculated permeated amount were considered equivalent to the 
Reference formulation. Subsequently a DPC-test was customized to identify only 
equivalent formulations as in vitro similar. It was possible to group all the equivalent 
formulations in a set called the equivalent space. After customization, it was shown that 
a TDT with     will classify as in vitro similar to the Reference formulation only 
formulations that were also equivalent. Additionally two examples of computer-assisted 
formulation optimization were introduced. However, the need of further improvement in 
the model and the limitations of the conclusions are highlighted. 
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6.2. Introduction 
The bioavailability of an orally administered drug is largely determined by the speed at 
which the drug crosses the gastrointestinal mucosa and reaches the blood stream. The 
speed at which a drug crosses a mucosa or a membrane is known as permeability and 
can be experimentally measured in vivo with humans and animals [103-106], or in vitro 
using cell lines and artificial membranes [107-112]. Due to its high morphological and 
physiological resemblance to intestinal cells and its spontaneous polarization into 
monolayers, the Caco-2 cell line model [113] is a very common procedure to study in 
vitro permeability. This model is useful to study transcellular and paracellular transport 
of drugs as well as transport events mediated by transporters [114]. Altogether, 
experiments performed with Caco-2 cells are considered the golden standard for in 
vitro prediction of intestinal drug permeability and absorption.[107, 115].  
However, permeability experiments based on Caco-2 cells are normally performed with 
totally dissolved substances (drug and additives if used), which restricts the possibility 
of studying the effects of complete drug formulations on absorption. Furthermore, donor 
concentrations used in these experiments are normally constant, arbitrarily chosen and 
do not represent appropriately the in vivo situation, in which the drug concentration at 
the apical side of the enterocytes is variable and depends on the release out of the drug 
formulation.  
As it has been stated in sections 3, 4.2 and 5.2, drug release from a formulation can 
also play an important role in the absorption and bioavailability of drugs administered as 
oral solid forms. Therefore, a tool to simultaneously study in vitro dissolution and 
permeability can be of great utility during the drug formulation development process to 
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study the effect of drug release and excipients on oral absorption in an easy and 
inexpensive way, which ultimately can lead to an optimization of the drug formulation. 
A d/p-system that allows the evaluation of complete solid oral dosage forms in an open 
system using dynamic flow conditions was presented by Motz et al [60]. This d/p system 
has been improved to allow continuous measurements of the drug concentrations in the 
different compartments of the device [61] and continuous monitoring of the Caco-2 cells 
monolayer integrity by measuring the transepithelial electrical resistance (TEER) [62]. 
The d/p-system has also been recently adjusted to perform experiments with artificial 
membranes [63]. 
The d/p-system described by Motz et al [60] is schematically shown in Figure 6.1 and 
consists of two main parts. The dissolution module part is a flow through dissolution cell 
(USP apparatus 4). It is connected in line with the second part, the permeation module 
which enables the setup of a Transwell® with a Caco-2 cell monolayer. The apparatus 
includes an automated sampling and detection devices using a sequential injection 
analysis (SIA). As dissolution and permeation require different flow rates the dissolution 
and permeation modules are connected with each other by a stream splitter. 
As it was stated in sections 3 and 5.2, declaring in vitro similarity of ER formulations is 
still an unresolved problem and methodologies able to link in vitro dissolution to an in 
vivo performance variable are highly desirable. Therefore, having two solid oral dosage 
forms of the same drug and strength, this d/p-system can help to predict whether a 
similar in vivo performance from the two formulations is expected or not. Moreover, after 
applying an adequate mathematical model of the d/p-system, a computational tool can 
be generated to predict the permeated amounts in the basolateral compartment in this 
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device from any dissolution profile obtained with the USP 4 apparatus. Therefore, when 
comparing the dissolution profiles between two formulations, it could be possible to 
predict in which cases the differences in release kinetics are large enough to produce 
significant differences in the permeability compartment of the d/p-system.  
 
 
Figure 6.1 Schematic illustration of the d/p-system according to [60-63]. A, B and D are the 
sampling ports for apical, dissolution and basolateral compartments. KRB is the working buffer (Krebs 
Ringer Buffer), UV-VIS and PMT-FL are detector for UV and fluorescence respectively. EVOM is an 
epithelial voltohmmeter for TEER monitoring.  
 
An ER formulation is usually designed pursuing two main objectives: 1) achieving safer 
and more constant in vivo concentrations of the administered drug, or 2) decreasing the 
administration frequency to improve compliance of the patient [29]. In both cases a 
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release as slow as possible is desired. The d/p-system complemented with the strategy 
presented here to predict equivalent formulations can be used to establish how slow the 
released of an ER can be without compromising its in vivo bioavailability. This would be 
expected to be proportional to the permeated amount in the system. Additionally, 
formulation optimization can be performed by predicting what formulations would lead to 
the largest amount of permeated drug in the permeation compartment or would have a 
slow release without compromising bioavailability, represented in this device by the 
permeated amount in the permeation module. 
The aim of this work was first to efficiently model the data from the ER propranolol 
tablets in the d/p-system and secondly to identify through simulations, what formulations 
would be equivalent (in terms of permeated amount in the basolateral compartment (B)) 
to the ER tablets analyzed experimentally (considered as the Reference formulation). 
This group of equivalent formulations was considered as the equivalent space (eq-
space). Once the critical differences in dissolution were established, TDT, a DPC-test, 
was customized to identify as in vitro similar only dissolution profiles from formulations 
with high probabilities of being equivalent to the Reference formulation. Additionally, 
nonlinear optimization was employed to predict what formulation would lead to the 
largest amount of permeated drug in the B compartment. The same method was 
employed to predict what formulation from the eq-space could have the slowest release. 
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6.3. Materials and Methods 
All the experimental data were taken from the work of Gantzsch et al [63], in summary,  
ER tablets with 10 mg propranolol were prepared according to Motz et al [60],  
Caco-2 cells following an established protocol [60, 61] Passages 61 – 70 within 21 – 25 
days after seeding were used for experiments. Only Transwells® showing TEER values 
above 300 Ω*cm² were used.  
Experiments were performed in an automated apparatus (d/p-system) [60-62]. Two 
propranolol tablets were inserted in the flow-through dissolution cell for each 
experiment. At certain defined time points, sampling took place at the apical (A) and 
basolateral (B) compartment of the FTPC. For a detailed description see [63] .  
 
6.3.1. Mathematical Modeling 
Concentration of the drug in the Dissolution module was described by the Weibull 
function (equation 6, section 3.3). Fitting of the Weibull function was performed using a 
nonlinear least square fit. The dose from the formulation      was considered as an 
unknown due to the variability of propranolol content in the tablets (CV = 13%). 
The transit through the d/p-system was modeled through a two-compartment pharmacokinetic model 
according to  
 
 
Figure 6.2.  
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Figure 6.2 Illustration of the pharmacokinetic two compartments model for d/p system.  
 
Change in D (mass in the dissolution module) was described by equation 16: 
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equation 16 
In which      and    are defined as in equation 6,       is the flow rate leaving the 
dissolution port, and    is the volume of the dissolution module (       ).  
Change in A (mass in the apical Compartment) was described by equation 17: 
  
  
  
 
   
     
     
  
            
     
  
 
equation 17 
   is the absorption constant of the drug through the basolateral compartment,       is the flow rate leaving 
the apical compartment, and    is the volume of the apical compartment. (     ). The factor 
 
   
 describes the 
split of       into       and       shown in  
 
 
Figure 6.2. A tlag of 4 minutes was considered between compartments D and A 
according to times measured experimentally.  
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Change in B (mass in the basolateral compartment) was described by equation 18:  
  
  
       equation 18 
 
6.3.2. Construction of Equivalent Space (Eq-space) 
The strategy used to identify equivalent formulations was similar to the one described in 
section 5.3.1 and illustrated in Figure 6.3. In vitro dissolution profiles were simulated 
for several formulations by modifying the Weibull model parameters and the permeated 
amounts were generated using the model described in the previous section.  
Inter-individual variability (IIV) was include for each parameter in the model to fit the 
reported experimental variability. In total, 1000 equivalence simulated studies per 
scenario were conducted. In each study, 12 tablets of the Reference formulation and 12 
tablets of the Test formulations were generated by Monte Carlo simulations. 
Equivalence between formulations was determined by calculating 90% confidence 
intervals (90%CI) of the ratio between Test and Reference means (n=12) after log-
transformation of the permeated amount. The formulations were considered equivalent 
if the 90%CI of the ratios were contained within the acceptance interval of 80.00 – 
125.00%. Eq-space was delimited by bounding the Reference formulations with high 
chances of being non-equivalent (      ). Once the Eq-space was delimited, TDT, a 
DPC-test, was customized to declare the formulations that are likely to be non-
equivalent as non-similar, using the same procedure as in section 5.4.3. 
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Figure 6.3 Strategy for building the equivalent spaces and customize a DPC-test.  
 
6.3.3. Dissolution Profile Comparisons 
Dissolution profiles from the Reference and Test formulations were compared using the 
DPC-tests described in section 4.3.4. 
 
6.3.4. Customization of TDT 
As described in section 5.4.3 Sim-spaces of TDT at increasing values of  were 
constructed in order to find the maximum  at which all the formulations declared as 
similar uisng this test are also equivalent. 
 
6.3.5. Formulation Optimization  
Using the same simulated dissolution profiles from Test formulations as in the previous 
section, the cumulative permeated amount was calculated for each Test formulation. 
The formulations with larger calculated permeated drug amounts were considered as 
the optimized formulations. Similarly the t85 of all the equivalent formulations was 
calculated to identify the equivalent formulations with the longest t85. 
 
 
 
 
 
Prediction of Equivalence in a Combined Dissolution and Permeation System using customized 
DPC-tests 
______________________________________________________________________________ 
90 
6.4. Results 
6.4.1. Model Fitting of the Combined Dissolution and Permeation Data 
Dissolution data was modeled by the Weibull function and after fitting the 
average profile was described by equation 6 with                         , 
             and                      
    . Data presented as a 
mean      . The corresponding fitting plot is shown in Figure 6.4. For the 
permeation into the basolateral compartment, a permeation constant          
                was calculated. The fitting plot is shown in Figure 6.5. 
 
Figure 6.4 Fitting of the data from dissolution module. Experimental data (•) and predicted 
values (solid line), data presented as mean and range     .  
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Figure 6.5 Fitting of the data from the basolateral module. Experimental data (•) and predicted 
values (solid line), data presented as mean and range     .  
 
6.4.2. Equivalent Space 
Figure 6.6.a shows the in vitro dissolution profiles of the experimental formulation, for 
this purpose considered the Reference formulation and the dissolution simulated 
profiles for several Test formulations. On Figure 6.6.b, the contour plot displays the 
probability of a Test formulation for being non-equivalent (in terms of permeated 
amount) to the Reference formulation. It can be observed that Test formulations 1-3 
have high probabilities of being non-equivalent, while Test formulation 4 has a low 
probability of being non-equivalent. Similar to section 5.4.2, the Eq-space is delimited by 
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separating the formulations based on a probability      of them being non-equivalent. 
All the formulations declared as similar with PT presented differences in the permeated 
amount compared to the Reference formulation of less than 0.8%. 
 
6.4.3. Customization of TDT 
Figure 6.7 shows two different similarity spaces (Sim-space) for TDT at different values 
of . A  of 8 is the maximum  at which all the formulations declared as similar with this 
test are also equivalent in terms of permeated amount of drug in the d-p system. This  
value represents the average tolerated difference (in %) between two formulations at 
any time point to produce equivalent formulations for the criteria of permeated amount.  
 
6.4.4.  Formulation Optimization 
Figure 6.8 shows the calculated permeated amounts in the d/p-system for the 
formulations used as test formulations in previous experiments (Figure 6.6). The 
formulation with release kinetics described by a Weibull function with          
      and       showed the largest calculated permeated amount (       ) and is 
represented in the contour plot as Max PA. Its dissolution profile can be observed in 
Figure 6.10 in comparison to the Reference formulation. Similarly, Figure 6.9 displays 
the difference in release kinetics of the equivalent and non-equivalent formulations 
expressed as t85. The formulation with a release kinetics described by          
      and       was the equivalent formulation with the longest t85 (      ) and is 
denoted in the contour plot as Max t85. 
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Figure 6.6 Construction of the Eq-space and identification of non-equivalent formulations. 
On the left the color scale of the probability of being nonequivalent to the Reference formulation. 
Formulations with high probabilities of being nonequivalent are located in the purple area.   
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Figure 6.7. Sim-space and Customization of TDT Sim-Spaces of TDT at different values of . for 
propranolol formulations. 
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Figure 6.8. Counter plots of the calculated permeated amounts in the d/p-sytem. Max Pa, 
points to the formulation of largest calculated permeated amount (       ). 
 
 
Figure 6.9. Counter plots of the t85 of the formulations in combination with the equivalent 
space of the d/p-sytem. Max t85 points to the formulation with the maximum possible t85 (223 min) 
that is inside the equivalent space.  
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Figure 6.10. Dissolution profiles of the optimized formulations. 
 
6.5. Discussion 
It is highly desirable to link dissolution tests to in vivo performance of the formulation 
tested [28, 79]. In section 5 it was presented how to do make that link when and IVIVC 
model is available. However in early stages of drug development an IVIVC may not be 
always available and a fast and inexpensive system to study the effect of formulation on 
permeability can be of great use. In this study we also evaluated the potential of this 
d/p-system as a tool to predict equivalency of different formulations with a given 
Reference formulation as well as for computer-assisted formulation optimization.  
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It was possible to predict what formulations would be equivalent to the Reference 
formulation in terms of permeated amount in compartment B. In general, only 
formulations with very slow release kinetics lead to a calculated permeated amount 
significantly lower than the reference formulation. In agreement with the results in 
sections  4.4.3 and 5.4.2 and , PT showed very good statistical power and all the 
formulations declared as similar with this test differ less than 0.8% in the calculated 
permeated amount for the basolateral compartment. That reinforces the potential of this 
test in the sphere of quality by design where tools which detect small changes in a 
critical quality attribute (in this case dissolution) are highly needed.  
In the sphere of generic drugs, the regulatory agencies could use the strategy 
presented here to detect if an ER Test formulation is equivalent to an ER Reference 
formulation in the market. Moreover, by customizing a TDT DPC-test, a simple in vitro 
dissolution test, without the permeability module may be sufficient to prove equivalency 
between two ER formulations. Previously, it must be proven that, for one, the excipients 
of the formulation do not affect the absorption of the drug, for two, the drug should not 
be a prodrug and it should not have a narrow therapeutic index or be intended to be 
absorbed in the oral cavity. Nevertheless, in order to achieve this level of reliance on the 
information generated by this strategy, it must be first verified that the d/p-system is a 
good representation of the in vivo case, which only can be concluded with further 
experiments. Likewise, the mathematical model can be improved to include the whole 
geometry of the GI tract and the inferences about the in vivo case would be more 
reliable. More generally, at least for ER formulations of BCS class I drugs like 
propranolol, in which absorption is expected to be driven by the release kinetics, the 
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strategy presented here is a reasonable approximation that can be improved step by 
step to identify equivalent formulations. 
If the objective of the formulation development is to design an oral solid dosage form 
with the highest possible bioavailability, it is of advantage to predict what formulation 
would exhibit the largest permeated amount in a d/p-system. Likewise, if the objective of 
the formulation development is to design a formulation with the slowest possible release 
to achieve safer plasma concentration or decrease administration frequency without 
sacrificing bioavailability, it is of advantage to predict which of the formulations of the 
eq-space has the slowest release. We presented in this work a computer-assisted tool 
to help in the formulation optimization process. This tool can be employed to maximize 
the permeated amount of drug in the d/p-system which ultimately could represent a 
maximized absorbed drug in vivo. Similarly it can be used to find the equivalent 
formulation with the slowest possible release kinetics or in general an equivalent 
formulation with a specific desired kinetics. Nonetheless, this method is constrained by 
the same limitations as in the case of identifying equivalent formulations (the uncertainty 
of how good the d/p-system mimics the in vivo case), but also retains the same improve 
opportunities.  
All the simulations were performed mimicking the typical experiment in the d/p-system 
which is performed for no more than 4 hours to assure the integrity of the Caco-2 cell 
monolayer. This time restriction is mathematically equivalent to an absorption window of 
4 hours and may not mimic properly the in vivo case. Using the mathematical model it 
would be possible to explore longer absorption windows that are not possible 
experimentally. Nevertheless, It must be considered that the results obtained from eq-
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space, customization of TDT as well as formulation optimization are valid only for an 
absorption window of four hours and that different absorption windows may lead to 
different results.  
The mathematical model presented here can also be used to detect which setup 
variables (flow rates and volumes) have a stronger effect on the concentrations in the 
apical and basolateral compartments, therefore it can be determined whether the 
discrimination power of the d/p-system, i.e. the capacity to transform differences in 
dissolution into differences in the permeated amounts can be increased by a different 
setup. Also, deeper explorations can be performed to check, by simulations, if the 
system can be improved by mounting more permeability units after the port D to 
simulate a segment of the intestine exposed to decreasing concentrations of the drug. 
In general this mathematical model can be used to explore different alternatives of the 
apparatus setup to optimize it or to mimic better the in vivo case. 
The presented mathematical model described reasonably well the experimental data. 
However, it is based on limited data (only one formulation) with high variability in all the 
ports sampled. Therefore conclusion must be drawn carefully and considering that the 
model must be improved considerably by including more experimental data. 
Additionally, the step in the splitter pump can be modeled differently by including 
expressions that describe the diffusion in the transit compartments, since the transit 
volume in the connecting tubes is almost 10 mL and the transit time is between 4 and 7 
minutes. 
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6.6. Conclusions 
A mathematical model was successfully developed to describe the experimental data of 
a d/p-system. Taking the tablets evaluated experimentally as a Reference formulation, 
the mathematical model was used to predict which formulations would be equivalent in 
terms of the permeated amount in the basolateral compartment to the Reference 
formulation. The group of equivalent formulations was called the eq-space, and it was 
possible to customize the DPC-test TDT in such a way that when the customized test (a 
TDT with    ) declares a formulation as in vitro similar to the Reference formulation, 
these formulations will most likely be equivalent regarding their permeated amount in 
the basolateral compartment. Through linear optimization it was possible to identify the 
equivalent formulations which would exhibit the longest possible t85 or the largest 
amount of permeated amount in the basolateral compartment. The mathematical model 
can also be used to evaluate modifications in the apparatus setup and configuration. 
However, the model must be further improved, mainly by the inclusion of more 
experimental data and better description of the transit between the compartments.  
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7. Summary and Outlook 
 
Dissolution testing has been widely used as a global indicator of the ability of a dosage 
form to release API, and in doing so enable it to reach its site of action. Furthermore, 
comparative dissolution testing has been explored as a tool to evaluate equivalency 
between formulations. However, the current official procedure to compare dissolution 
profiles, the f2 similarity factor, lacks solid statistical foundation and the level of 
statistical uncertainty is unknown. Moreover, the limits of the f2 similarity factor to 
declare in vitro similarity (f2 ≥ 50) not derived from any specific biopharmaceutical 
property. Such a test therefore cannot be considered as a good predictor of in vivo 
performance, especially in the case of ER formulations. The aim of this work was to 
design, develop and explore new DPC-tests with stronger statistical basis than the 
currently employed methodologies f2 similarity factor, and to link the limits of rejections 
of these new DPC-tests with significant differences in important biopharmaceutical 
properties with more predictive power of in vivo formulation performance. Examples of 
DPC-test customization have been presented for three ER formulations (metformin, 
diltiazem and pramipexole) using IVIVC models; one example of DPC-test 
customization for a propranolol ER formulation using a d/p-system has been also 
illustrated. In summary:  
 
Exploration of the two new DPC-Tests 
 Two new statistical tests, the PT and the TDT, have been presented for 
dissolution profile comparison. In these tests both type-I and type-II errors can be 
quantified; both tests also have stronger statistical basis than the current 
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alternative (e.g., the f2 similarity factor). The two new tests showed acceptable 
robustness at standard conditions of variation (CV95 ≤ 0.1). 
 A strategy to design and perform a dissolution profile comparison under typical 
principles of statistical experimental design has been presented.  
 An optimized time sampling strategy was introduced in the current work. This 
strategy should be employed when possible in DPC-tests to avoid artificial 
discontinuities in the statistical power. The exception to the recommended use of 
such a strategy is in the case of PT which is not susceptible to this effect. 
 
Customization of DPC-Tests 
 A DPC-test, TDT, was customized for three different ER formulations and its 
limits of rejection linked with an in vivo attribute: the high probability of being 
nonbioequivalent. Formulations that proved to be similar to the Reference 
formulation using a customized DPC-test (TDT with δ of 3.6, 5.95, and 3.45 for 
metformin, diltiazem and pramipexole respectively) are likely to be bioequivalent. 
Such a result demonstrates a clear application of formulation-specific DPC-test in 
the exploration of post-approval changes by a manufacturer, or the evaluation of 
BE between products from different manufacturers. The use of such DPC-tests 
could decrease the need for future human BE studies and reduce costs of 
production.  
 Tlag and ka were found to be the drug/formulation parameters that influenced BE-
space to the greatest degree for the pramipexole ER formulation. 
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 MDT or MRT were not suitable for bioequivalence prediction in the case of the 
ER formulations investigated (metformin, diltiazem and pramipexole). 
 The presented work leads to the suggestion that case-specific studies, using 
IVIVC or d/p-systems may support the biowaiving of ER drug formulations, based 
on customized DPC-tests.  
 
Application of DPC-test customization in a d/p-system 
 A mathematical model was successfully developed to describe the experimental 
data of a d/p-system. This mathematical model could be used to predict which 
formulations would be equivalent to a Reference formulation in terms of the 
permeated amount in the basolateral. 
 By establishing in vitro similarities between Test and Reference formulation, a 
customized TDT (    ) could be used to identify formulation likely to be 
equivalent with respect to the permeated amount in the basolateral compartment 
of the d/p-system.  
 A computer assisted tool for formulation optimization has been presented which 
allow for the design of formulations with larger permeated amounts in the d/p-
system and longer t85. 
 
Properties of PT 
 PT was the most robust and powerful test in all the conditions studied (even in 
conditions of high variability CV95 ≤ 0.2 and reduced sample sizes). Differences in 
Cmax and AUC produced by formulations declared as similar with PT were less 
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than 1.5% for the metformin, diltiazem and pramipexole ER formulations. This 
test is therefore strongly recommended for identifying small differences in 
dissolution.  
 In the case of the propranolol ER formulation, PT also showed excellent 
statistical power. All the formulations declared as similar with this test in the d/p-
system differed by less than 0.8% in the calculated permeated amount in the 
basolateral compartment of the system.  
 
Outlook 
While the work presented in this thesis shows a promising application of both PT and 
TDT, it must be considered that more experimental confirmation is needed to prove the 
suitability of the new DPC-tests as alternatives for performing dissolution profile 
comparison. In particular, experimental verification of the lack of effect for iid-conditions 
(section 4.3.7) is necessary to ensure an adequate performance of the TDT under the 
standard (no iid-conditions). 
Another step that should be explored is the linking of customized DPC-tests with clinical 
outputs or pharmacodynamics biomarkers instead of BE probabilities. This could be 
achieved using pharmacokinetic pharmacodynamic (PK/PD) modeling which, of course 
demands a deeper understanding of the pharmacology of the drug as well as a higher 
level of detail in the mathematical modeling. 
The mathematical model employed to describe the data from the d/p-system has many 
opportunities for improvement. Specifically the inclusion of more experimental data and 
a better description of the transit between the compartments should be considered. 
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Similarly, attractive opportunities such as the exploration of formulation and apparatus 
optimization, and inclusion of data from drugs which are substrates of active 
transporters remain open for further development.  
It should be emphasized that the excellent statistical power exhibited by the PT is a very 
promising outcome of this thesis. It is worth exploring the potential of PT as a quality by 
design tool due to its ability to detect even small differences in dissolution profiles. 
When dissolution profiles are used as a critical quality attribute (CQA), the performance 
of the formulation will not be compromised as long as similarity is declared by PT. Also 
knowledge of a manufacturing process can be improved by checking the influence of 
different process variables (compression pressure, granulation time, percentage of 
polymer etc.) on this CQA, and identifying the changes in these variables required to 
produce a non-similar dissolution profile.  
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8. Abbreviations 
 
 
90% CI 90% confidence intervals  
A Apical compartment 
API Active pharmaceutical ingredient (s) 
AUC Area Under the Curve 
B Basolateral compartment 
BCS Biopharmaceutical classification system  
BE Bioequivalence 
BE-space Bioequivalent space 
Cmax Maximum plasma concentration  
CQA critical quality attribute 
D Dissolution port in the d/p-system 
d/p-system Dissolution permeability system  
DPC-test Dissolution profile comparison test(s) 
Eq-space Equivalent space 
EVOM Epithelial volt ohm meter 
FTPC Flow-through permeation cell 
GI Gastro-intestinal 
GIT gastro-intestinal tract  
iid-conditions Independent identically distributed 
IR immediate release  
KRB Krebs ringer buffer 
MDT Mean Dissolution Time 
MRT Mean Residence Time  
PK Pharmacokinetic (s) 
PK/PD pharmacokinetic pharmacodynamic 
PT Permutation test 
Sim-space Similarity space 
t85 Time required to release 85% of the drug from an oral solid dosage form 
TDT Tolerated difference test 
TEER Transepithelial electrical resistance 
  
  
  
  
  
  
 
 
 
 
 
Annexes 
______________________________________________________________________________ 
107 
9. Annexes  
 
          Time Points   
 
(1-α) 
4 5 6 7 8 9 10 
0.9 83.00 82.00 81.00 80.43 79.88 79.44 79.00 
0.95 86.25 84.80 83.67 82.71 82.13 81.44 81.00 
0.975 89.00 87.20 85.83 84.86 84.00 83.33 82.70 
0.99 92.00 90.00 88.33 87.14 86.25 85.44 84.70 
0.995 94.25 91.80 90.17 88.86 87.75 86.78 86.10 
0.999 98.50 95.80 93.67 92.14 90.88 89.78 88.90 
0.9995 100.25 97.20 95.00 93.43 92.00 90.89 90.00 
A.1. Rejection Values for TDT for several time points and uncertainty. 
 
 
A.2. AUC BE-Space Metformin. 
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A.3. Cmax BE-Space Metformin. 
 
A.4. AUC BE-Space Diltiazem 
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A.5. Cmax BE-Space Diltiazem 
 
A.6. AUC BE-Space Pramipexole 
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A.7. Cmax BE-Space Pramipexole 
 
A.8. Customization of TDT (Metformin) 
Annexes 
______________________________________________________________________________ 
111 
 
A.9. Customization of TDT (Diltiazem) 
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A.10. BE-Spaces under different values of V1, V2, CLD. 
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A.11. BE- Spaces at different values of kel. (Pramipexole). 
 
A.12. BE-Spaces at different values of kel. (Metformin). 
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A.13. Effect of Number of volunteers on BE-Space (Metformin)
 
A.14. Effect of Number of volunteers on BE-Space (Diltiazem) 
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A.15. Comparison of BE-Spaces to a)MDT and b)MRT (Metformin). 
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A.16. Comparison of BE-Spaces to a)MDT and b)MRT (Diltiazem). 
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A.17. Reduction in the Cmax BE-Space at different values of Clearance. The reduction is 
significant when the kel/ka ratio is 0.2 or higher. The AUC BE-Space is not affected (lower right). 
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A.18. Comparison of PK models of Metformin and Diltiazem. Dissolution, PK profile, and 
relationship between dissolution and concentration in the central compartment. 
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A.19. Relationships between Sim-Space and MDT and MRT. Several formulations can have the 
same MDT but different MRT for both metformin and diltiazem, no relationship was observed bwtween 
the BE-Space or the Sim-space and MDT or MRT. 
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10. Scientific Output 
 
 
Original Papers  
 
 J.D. Gomez-Mantilla, V.G. Casabo, U.F. Schaefer, C.M. Lehr, Permutation Test (PT) 
and Tolerated Difference Test (TDT): Two new, robust and powerful nonparametric 
tests for statistical comparison of dissolution profiles, Int J Pharm, (2012). 
 
 
 J.D. Gomez-Mantilla, V.G. Casabo, U.F. Schaefer, T. Lehr, C.M. Lehr, Identification of 
Non-Bioequivalent Extended Release Formulations by Tailor-Made Dissolution Profile 
Comparisons Using In Vitro-In Vivo Correlation Models, (Submited). 
 
 
Conference Abstracts  
 
 J.D. Gomez-Mantilla, V.G. Casabo, U.F. Schaefer, C.M. Lehr, Permutation Test (PT) 
and Tolerated Difference Test (TDT): Two new, robust and powerful nonparametric 
tests for statistical comparison of dissolution profiles 
8th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical 
Technology, Istanbul, Turkey, March 2012 
 
 
 J.D. Gomez-Mantilla, V.G. Casabo, U.F. Schaefer, T. Lehr, C.M. Lehr, Tailor-made 
dissolution profile comparisons using In Vivo-In Vitro Correlation Models  
22nd Population Approach Group Europe (PAGE), June 2013, Glasgow, Scotland 
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